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Abstract 
 Cancer cells have acquired the ability to survive by up-regulating survival pathways or 
down-regulating cell death pathways that results in their resistance to apoptosis. Integral players 
involved in the activation or inhibition of apoptosis include the tumor suppressor p53 and the 
Bcl-2 family of proteins. In 50% of human cancers p53 is mutated resulting in inactivation of its 
tumor suppressor activity, however, in the remaining cancers p53 is functionally inhibited by its 
direct interaction with the MDM2 protein. This interaction has been extensively studied and has 
resulted in the discovery of small molecule MDM2-p53 interaction inhibitors like SAR405838. 
The Bcl-2 family of proteins, key regulators of apoptosis, has inspired a plethora of 
investigations aimed at targeting this family to activate apoptosis in tumor cells. Examples of 
these apoptosis-inducing agents are the Bcl-2/Bcl-xL inhibitors ABT-737 and ABT-263. 
Although these agents show promise in clinical trials for the treatment of cancer, it is fully 
expected that resistance to these drugs will develop. Here, I have investigated the acquired 
resistance mechanisms in vitro and in vivo to apoptosis-inducing small molecule anticancer 
agents in acute leukemia and osteosarcoma models.  
 Despite impressive initial antitumor activity, the tumor regression achieved by ABT-
737/ABT-263 and SAR405838 in xenograft models of acute leukemia is transitory; tumors 
eventually regrew after treatments were terminated, suggesting emergence of resistance to both 
classes of drugs. Analysis of the regrown tumors initially treated with the inhibitors showed that 
 xi 
the acute leukemia cells acquire resistance to SAR405838 by mutation of the p53 gene or 
compromised p53 function, and to ABT-263 through down-regulation of pro-apoptotic Bcl-2 
family member BAX. Combination and sequential treatment of SAR405838 and ABT-263 
achieved longer term tumor regression without signs of toxicity than either agent alone in acute 
leukemia models.  
 In the osteosarcoma model, which harbors an amplified MDM2 gene and wild-type p53, 
only in vitro exposure to SAR405838 resulted in acquired resistance whereas in vivo exposure 
did not. Similar to the findings in the acute leukemia models, analysis of the SJSA-1 cells that 
developed resistance in vitro to SAR405838 showed that p53 is mutated in the DNA binding 
domain. In comparison, a number of cell lines were established by culturing tumors that regrew 
after SAR405838 treatment and, surprisingly, these sublines retained sensitivity to SAR405838. 
Analysis of these sublines showed that p53 either maintains its wild-type status or harbors a 
single heterozygous C176F mutation located in the DNA binding domain of p53. Computational 
modeling suggests that the p53 C176F mutant is still functional. Taken together, these data 
suggest that both in vitro and in vivo models of resistance should be employed in order to better 
identify resistance that may occur in a clinical setting.   
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Chapter 1  
Introduction 
 The treatment of cancer has improved greatly over the last several decades, mainly due to 
the development of highly efficacious chemotherapeutics and targeted therapies.  However, the 
ability of cancer cells to develop resistance to drug treatment remains a significant impediment to 
successful disease treatment.  Numerous investigations have identified a myriad of mechanisms 
in which cancer cells can elude drug therapy, and it has become evident that resistance exists 
against every effective drug.  The determination of the mechanisms of drug resistance can help to 
identify patients that may benefit the most from the drug and to develop rational treatment 
strategies to overcome resistance.   
 Drug resistance results when diseases become tolerant to pharmaceutical treatments.  The 
concept was first recognized when bacteria became resistant to certain antibiotics and has now 
been identified in other diseases such as cancer. Several mechanisms of resistance have been 
identified such as drug inactivation, drug efflux, drug target alterations, DNA damage repair, cell 
death inhibition and microenvironment-mediated resistance
1-3
. For the purpose of this 
dissertation I will primarily focus on the mechanisms of resistance involving resistance of cancer 
cells to cell death induction by apoptosis inducing agents. 
 Cells have an inherent ability to self-destruct called programmed cell death or apoptosis. 
Defects in the apoptotic machinery can eventually lead to expansion of populations of cancerous 
cells.  Resistance to apoptosis can also increase the tumor cells ability to escape analysis by the 
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immune system.  Furthermore, defects in the apoptosis pathways can result in cancer cell's 
resistance to therapy. Thus, resistance to apoptosis has been termed one of the hallmarks of 
cancer and is an important clinical problem.  This dissertation will focus on elucidating the 
mechanisms of resistance in cancer models, both in vitro and in vivo, that arise as a result of 
treatment with small molecule inhibitors designed to target defects in the apoptosis machinery. 
More specifically, I will focus on the mechanisms of resistance to inhibitors of the p53-MDM2 
interaction and anti-apoptotic protein members of the B cell lymphoma 2 (Bcl-2) family. The 
results from these studies may lead to the development of rationale treatment strategies aimed at 
overcoming cancer drug resistance. 
 
p53 
  Over 30 years ago, the p53 gene was first identified as an oncogene, but over ten years 
later was found to be a tumor suppressor
4,5
. The p53 gene contains 11 exons spanning 20 kilo 
bases in chromosome 17p.  Both the loss of chromosome 17p and p53 inactivating mutations are 
common in cancers. The p53 gene was implicated in the rare inherited condition, Li-Fraumeni 
syndrome, which is associated with frequent occurrence of several types of cancer in affected 
families 
6
.  Furthermore, it was determined that the p53 protein does not function properly in 
most human cancers.  In order to investigate the role of the p53 gene in mammalian development 
and tumorigenesis, mice with p53 deficiency were utilized. Observations showed that the mice 
deficient for p53 were prone to develop cancer
7
. In humans, approximately 50% of tumors 
harbor a mutated form of TP53 (gene that encodes the p53 protein) and in the remaining 50% 
p53 can be altered in a myriad of ways
8,9
.  A large body of accumulated studies has demonstrated 
that all cancer cells harbor either defective p53 or malfunctions in the p53 network. 
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Figure 1.1 p53 signaling pathway 
 
 The tumor suppressor protein p53 is a multifunctional transcriptional factor that regulates 
cellular processes that affects DNA repair, senescence, angiogenesis, cell cycle, differentiation 
and apoptosis 
5
 (Figure 1.1
9
). In unstressed cells p53 exists at very low concentrations, however, 
under stress (DNA damage, activated oncogenes, etc) p53 protein accumulates in the cell.  Upon 
accumulation the p53 protein will bind in its tetrameric form to the p53 response elements, which 
include a large and versatile group of responsive genes
10
. Thus, p53 acts as a transcription factor 
controlling these important cellular processes.  Without p53, damaged and stressed cells continue 
to multiply and thus are likely to become cancerous.  There are several mechanisms of 
inactivation of p53 that have been found in human cancer. These mechanisms include mutations 
in the p53 gene
8
, increased degradation of p53 by the direct binding of the MDM2 
oncoprotein
11,12
, deletion of the carboxy terminal domain of p53, mutations in downstream 
regulators and mislocalization of p53 to the cytoplasm instead of the nucleus
5,13
. 
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Figure 1.2 Cytosolic and mitochondrial p53 apoptotic pathways 
 
 One of the more prominent cellular responses to p53 is the activation of apoptosis.  
Apoptosis signals can employ two pathways: the extrinsic pathway, which is activated through 
cell surface receptors, or the intrinsic pathway (see section titled Bcl-2 Family for more details), 
which responds to stress signals
14
.  The Bcl-2 family of proteins play a central role in the 
activation of the intrinsic apoptotic pathway (Figure 1.2
15
). Apoptosis is induced by p53 
primarily through induction of the pro-apoptotic Bcl-2 family members, such as NOXA and p53 
upregulated modulator of apoptosis (PUMA)
16,17
. The PUMA protein is able to bind to the 
mitochondrial anti-apoptotic proteins such as Bcl-2, Bcl-xL, Bcl-w, Mcl-1 and Bcl-2A1, whereas 
NOXA is only able to bind to Mcl-1 and Bcl-2A1
18
.  Apoptosis is initiated once PUMA and/or 
NOXA inhibit the Bcl-2 anti-apoptotic family members
19
.  Apoptosis can also be directly 
activated by translocation of the p53 protein to the mitochondria resulting in activation of the 
pro-apoptotic Bcl-2 family members, such as BAX and BID
20,21
. The mechanism of 
transcription-independent p53-mediated tumor suppression is another route in which p53 can 
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activate apoptosis. Complexation of the DNA-binding region of p53 with the anti-apoptotic 
proteins Bcl-2 and Bcl-xL frees their pro-apoptotic family members to activate apoptosis
22
.  
 Initially, p53 was termed the 'guardian of the genome' due to its ability to mediate G1 
arrest as a result of DNA damage
23
. Transient or irreversible p53-mediated cell cycle arrest 
involves the transcriptional activation of the cyclin-dependent kinase (CDK) inhibitor p21
24,25
. 
Enhanced levels of p21 inactivate the kinases responsible for driving cell cycle progression
26
. 
Analysis of cells from p21 deficient mice revealed that activation of p21 by p53 plays a major 
role in mediating the G1 cell cycle arrest
27
.  
 
Figure 1.3 Frequency and distribution of TP53 mutations 
The p53 protein comprises 393-residues that contains an NH-terminal transactivation domain, a 
proline-rich SH3 ligand, a core DNA-binding domain, a tetramerization domain and a carboxy-
terminal regulatory domain
28
. A histogram of p53 missense mutations identifies the frequency of 
each mutation
29
. 
 
 As mentioned previously, p53 function in cancers can be inactivated due to mutations 
within the TP53 gene.  Mutations have been found in almost every region of the p53 protein, 
however, approximately 95% of the mutations identified occur in the sequence specific DNA 
binding domain (amino acids 100 to 300) (Figure 1.3
29
). Most frequently the tumor associated 
alterations in p53 result in missense mutations, which leads to the substitution of a single amino 
acid that can be stably expressed in the tumor cell
30
.  Currently, the p53 field has identified six 
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key residues that are most commonly mutated and have been terme                            
                                                                 generally lead to a loss of 
function of the wild-type activity of p53 (Figure 1.3)
28
. In many tumor cells where p53 harbors a 
single amino acid substitution its ability to express p53 is retained, despite the mutation.  These 
mutated p53 proteins are commonly more stable than wild-type p53 and are at higher 
concentrations in the tumor cells
13
.  
 
MDM2-p53 Interaction 
 In the remaining cancers that do not harbor mutated p53, p53 can be functionally 
inhibited by its primary cellular inhibitor, murine double minute 2 (MDM2).  Initially the MDM2 
oncogene was found overexpressed by amplification in a spontaneously transformed cell line 
(3T3DM)
31
. MDM2 contains a p53 binding domain at the N-terminus and a RING (really 
interesting new gene) domain at the C-terminus functioning as an E3 ubiquitin ligase, which 
targets both p53 and itself for degradation by the proteasome
32
.  The first functional role 
attributed to MDM2 was its ability to inhibit p53 transcriptional activation
33
. A common feature 
of many tumors, specifically tumors with wild-type p53, is they exhibit amplification of the 
MDM2 gene or altered expression of the MDM2 protein
32
. These facts lead to the conclusion 
that the major oncogenic role of MDM2 is to block the transcriptional activity of p53. 
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Figure 1.4 MDM2 and p53 auto-regulatory feedback loop 
  
 The MDM2-p53 interaction has been a highly investigated area in research and discovery 
of new cancer therapy.  MDM2 and p53 form an auto-regulatory feedback loop in which the two 
proteins mutually control each other's cellular level (Figure 1.4
34
).  When the level of MDM2 
increases, it binds to and inactivates p53 by blocking its transactivation domain and by targeting 
the protein for ubiquitin dependent degradation by the proteasome
33
.  MDM2 binding to p53 also 
induces the export of p53 out of the nucleus which inhibits p53's ability to access target genes
12
.  
The importance of MDM2 in the control of the activity of p53 was demonstrated when mice 
lacking MDM2 died as embryos, but additional deletion of TP53 rescued them from death
35
. 
MDMX, a homolog of MDM2, can also directly bind to the transactivation domain of p53 and 
inhibit the activity of p53, however, MDMX does not induce degradation of p53.  The tumor 
suppressor ARF accumulates in the nucleus where it forms stable complexes with MDM2 and 
sequesters it into the nucleolus, thereby preventing MDM2 from inhibiting p53 activity
36
. 
 MDM2 is clearly an important modulator of various pathways in the oncogenic process.  
The release of p53 from MDM2 leading to cell cycle arrest and apoptosis has emerged as an 
important interaction for the treatment and prevention of cancer.  High resolution crystal 
 8 
structures of the NH2 terminus of MDM2 complexed with short p53 peptides provided necessary 
information about the interaction
37
.  The structures show that the MDM2-p53 interaction 
involves a hydrophobic pocket in MDM2 with four key hydrophobic residues in p53, which 
include Phe19, Leu22, Trp23 and Leu26
34
. The identification of the well-defined pocket and key 
interactions involved in the binding of MDM2 to p53 provided the basis for the design of non-
peptide, drug-like small molecule inhibitors of the MDM2-p53 interaction to reactivate p53.       
 The Nutlins were the first class of bona fide, potent, specific and orally bioavailable small 
molecule MDM2 inhibitors
38
.   The Nutlins act by mimicking p53 and binding in the p53 binding 
pocket of MDM2, leading to the activation of cell cycle arrest, apoptosis and senescence in 
cancers with wild-type p53
39
. A derivative of Nutlin-3 with improved binding affinity to MDM2 
and pharmacokinetics, RG7112, was advanced into clinical trials
40,41
. RG7112 was well tolerated 
in patients with liposarcoma, however, some patients experienced hematological toxicity
42
. 
RG7112 is currently in Phase I clinical trials as a single agent for patients with advanced solid 
tumors or leukemia and in combination in patients with AML (http://clinicaltrials.gov).  
The MI compounds are a spiro-oxindole class of compounds designed by our laboratory.  
MI-219 binds to MDM2 with high affinity and specificity, particularly over MDMX
43
. Chemical 
modifications of MI-219 lead to the discovery of MI-77301 (SAR405838) which exhibits 
improved binding affinity to MDM2, cellular activity and pharmacokinetics
44
. The MDM2 
inhibitors are able to induce both cell cycle arrest and cell death in tumor cells. Studies using 
Nutlin-3, RG7112, MI-219 and MI-77301 (SAR405838) show that these inhibitors selectively 
inhibit cell growth and induce cell cycle arrest in p53 wild-type tumor cell lines
38,40,43,44
.   
 The effect of MDM2-p53 interaction inhibitors on normal tissue is of great importance 
when evaluating these inhibitors from a therapeutic standpoint.  Preclinical studies in mice have 
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shown good tolerability of the Nutlin and the MI compounds with no sign of toxicity
38,43,44
. In 
normal cells, the MDM2 inhibitors activate p53 and induce cell cycle arrest but not cell 
death
38,43
.  Radiation and chemotherapy treatment of mice induces profound apoptosis in small 
intestine crypts and the thymus, tissues that are highly susceptible to p53-induced apoptosis
43
. 
MI-219 treatment activates p53 with minimal p53 accumulation and does not result in apoptosis 
in normal tissues
43
. The exact mechanism for the lack of toxicity in normal tissues post MDM2 
inhibitor treatment is yet to be determined. 
 
Bcl-2 Family 
 Although p53 plays a prominent role in apoptosis induction, the Bcl-2 family are the 
master regulators of apoptosis at the mitochondria
14,45,46
.  The proteins in the Bcl-2 family 
regulate apoptosis in response to physiological prompts and cytotoxic agents
45
. While normal 
cells have low expression levels of the antiapoptotic Bcl-2 and Bcl-xL proteins, these proteins 
are highly overexpressed in many different types of human tumors. Overexpression of Bcl-2 
antiapoptotic proteins have been linked to poor prognosis in several types of cancer as well as 
clinical resistance to current cancer treatments
47
. Laboratory studies and clinical observations 
have established that overexpression of Bcl-2 or Bcl-xL causes cancer cells to become more 
resistant to chemotherapeutic agents, thus the development of agents that can inhibit the Bcl-2 
family of proteins demonstrates promise in the treatment of cancer
48
.   
 As mentioned above, apoptosis occurs through two distinct mechanisms, the extrinsic and 
intrinsic pathways.  The extrinsic apoptotic pathway is initiated by ligation of the tumor necrosis 
factor family leading to downstream activation of caspase-8, which in turn activates effector 
caspases such as caspase-3
49
. The intrinsic pathway is regulated by the Bcl-2 family of proteins, 
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which controls whether a cell lives or commits to death through the mitochondrial apoptotic 
pathway
50
. The Bcl-2 family can be divided into three groups based on sequence homology and 
function: first, the proapoptotic Bcl-2 homology domain (BH3)-only proteins (such as BID, 
BIM, PUMA, NOXA, and BAD), second, the multi-domain proapoptotic proteins (BAX and 
BAK) and lastly, the antiapoptotic proteins (Bcl-2, Bcl-xL, Bcl-w, Mcl-1 and A1) (Figure 1.5)
51
.  
The initiation of apoptosis requires both proapoptotic proteins and the related BH3 protein 
interaction domain.  Death signals result in the BH3-only proteins switching off survival function 
by inserting their BH3 domain into a hydrophobic pocket on their antiapoptotic relatives 
52
.
 
More 
simply, when the amount of proapoptotic proteins surmounts the binding ability of antiapoptotic 
proteins, apoptosis progresses (Figure 1.6).
 
 
Figure 1.5 Structure of the Bcl-2 family of proteins 
The Bcl-2 family of proteins is divided into three groups based on their Bcl-2 homology (BH) 
domains.  Proapoptotic and antiapoptotic proteins have 4 BH domains and the BH3-only 
proteins, contain only the BH3 domain
53
.  
  
 The BH3 domain and the presence of either BAX or BAK are necessary for the death 
function of the BH3-only proteins
54
. The targeted deletions of BAX or BAK produced mice with 
a relatively mild phenotype
55
. However, the deletion of both BAX and BAK resulted in mice 
with a large number of defects.  The essential roles of BAX and BAK in apoptosis were further 
emphasized in double knockout mouse embryonic fibroblast cells where the cells were resistant 
to a myriad of apoptotic stimuli
56
.  Once BAX and/or BAK are free from their anti-apoptotic 
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family members they homo-oligomerize and permeabilize the mitochondrian, a process termed 
mitochondrial outer membrane permeabilization (MOMP), releasing factors such as cytochrome 
c and SMAC promoting activation of the caspases resulting in cell death (Figure 1.6
2
)
46,53
.  
 
Figure 1.6 Bcl-2 protein family: key regulators of apoptosis 
   
 Over the last decade, BAX and BAK have been classified as homologs or functionally 
redundant.  However, there has been more recent evidence suggesting that BAX and BAK play 
different roles in apoptosis in various cell types.  In HCT116 human colon carcinoma cells, BAK 
is expendable for apoptosis induced by stimuli such as Bcl-2/Bcl-xL small molecule ABT-737, 
but not for fluorouracil-induced apoptosis
57
.  In both a leukemia and lymphoma model, the 
knockout of BAX conferred resistance to ABT-737
58
.  However, the loss of BAK or BAX has 
yet to be identified as a consequence of acquired drug resistance to apoptotic stimuli.   
 Evidence that further supports the potentially different roles of BAX and BAK are their 
different locations in the cell.  Upon apoptotic stimuli, BAX is primarily cytosolic and 
translocates to the mitochondrial outer membrane where it oligomerizes and inserts
53
.  
Conversely, BAK is primarily located in the cytosol where it inserts into the mitochondrial outer 
membrane by a C-terminal transmembrane domain
59
.  Controversy as to how BAX and BAK are 
activated leading to cell death is another area suggesting that these antiapoptotic proteins play 
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different roles in apoptosis.  It remains to be determined whether the BH3-only protein PUMA 
(p53 up-regulated modulator of apoptosis) can promote ligand-induced activation of BAX.  
However, Gallenne et al. suggested that PUMA is competent to trigger BAX activity by itself
60
.  
In healthy cells, BAK associates with Mcl-1 and Bcl-xL, but not with other antiapoptotic 
members such as Bcl-2 and A1.  Thus, BAK is held in check mainly by Mcl-1 and Bcl-xL and 
only induces apoptosis if freed from both
61
.   
 The balance between the pro- and antiapoptotic proteins in a cancer cell plays a huge role 
in whether a cell will commit to death or not. For example, a cell may express a large amount of 
antiapoptotic proteins that are available to bind and sequester their proapoptotic family members 
and therefore be protected from extreme levels of pro-death signaling, such as signals that would 
result from chemotherapy treatment. Conversely, a cancer cell can have a very small amount of 
antiapoptotic proteins leaving it ill-equipped to defend itself against stress. The cells with high 
levels of antiapop    c  r        r  ‘   r    ’ f r        w  r    c ll  w    l w l v l   f 
            c  r        r  ‘ r    ’ f r      62. Assays can be employed to measure whether a 
cancer cell is primed for death and thus how readily it will undergo apoptosis
63
. The ability to 
profile cancer cells has allowed for the determination of how tumor cells will respond to 
cytotoxic chemotherapy
64
.  Furthermore, profiling cancer cells has helped shed light on cancer 
cells that will readily undergo apoptosis when exposed to BH3 mimetics
65
. 
 Targeting the Bcl-2 family of proteins has proven to be a promising approach to the 
treatment of cancers with over-expression of Bcl-2.  The BH3 domain has been extensively 
studied including extensive crystallographic studies
52
.  These studies provided the building 
blocks for the development of BH3 mimetics.  BH3 mimetics are small molecules designed to 
mimic BH3 proteins by binding and sequestering Bcl-2 anti-apoptotic family members.  Several 
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natural product derivatives and rationally designed compounds have been developed as BH3 
mimetics, including ABT-737 and its oral analog ABT-263 (navitolax), ABT-199 and gossypol 
(AT-101)
66-69
.  
 AT-101 (gossypol) is a natural product derived from cotton seed, stem and root that is an 
oral pan-Bcl-2 inhibitor
70
. AT-101 binds with submicromolar affinity to Bcl-2, Bcl-xL and Mcl-
1
71
. The drug works by inducing apoptosis by acting as a BH3 mimetic and as a p53 independent 
activator of NOXA and PUMA
72,73
. The cytotoxicity of AT-101 may also be attributed to DNA 
cleavage and/or the generation of reactive oxygen species
73
. The phase I trials were promising; 
AT-101 was well tolerated in patients and demonstrated cytoreductive activities in several 
malignancies
69
. Unfortunately, phase II trials in prostate and lung cancers, both in single agent 
and combination treatment regimens failed to be clinically efficacious
69
. 
 Highly potent small-molecule inhibitors of Bcl-2/Bcl-xL have been designed including, 
ABT-737 and ABT-263 from Abbott Laboratories
66,67
. ABT-737 and ABT-263 have similar 
binding profiles, both of which bind with high affinity (Ki < 1 nM) to Bcl-2, Bcl-xL and Bcl-w. 
Consistent with its chemical binding profile to these Bcl-2 proteins, ABT-737/ABT-263 
effectively induces apoptosis in cancer cell lines with high levels of Bcl-2/Bcl-xL both in vitro 
and in vivo
67
. ABT-737/ABT-263 acts by binding to anti-apoptotic family members such as Bcl-
2, Bcl-w and Bcl-xL, but does not bind members such as Mcl-1 and A1.  The antagonization of 
these anti-apoptotic family members leads to the downstream activation of pro-apoptotic family 
members, such as BAX and BAK.  The efficacy of ABT-737/263 in inducing apoptosis is cell 
specific
74
.  In various in vivo models of small cell lung carcinomas (SCLCs), lymphoma, and 
myeloid leukemias, ABT-737/ABT-263 has been effective in causing tumor regression
67
. ABT-
263 clinical trials have been and are currently being conducted in patients with chronic 
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lymphocytic leukemia (CLL)
75
, lymphoma
76
 and lung cancer
77
. Partial response was observed in 
patients with relapsed or refractory CLL, however, ABT-263 had minimal success as a single 
agent in treatment of lung cancer
77
. Thrombocytopenia was observed in the clinical trials as the 
dose-limiting toxicity, because ABT-263 targets Bcl-xL which is critical for platelet survival
78,79
. 
Luckily, the platelet decrease was transient and reversible
75-77,80
.  
 Many studies have investigated Bcl-2/Bcl-xL inhibitors in combination with conventional 
chemotherapy agents and targeted therapies.  Potent synergistic responses have been observed 
between ABT-737 and dexamethasone in multiple myeloma patient samples
81
. Concurrent use of 
the S-phase blocker, zoledronic acid, with ABT-737 induces synergistic cell death in 
cholangiocarcinoma cell lines
82
.  Both ABT-737 and ABT-263 significantly enhance the activity 
of chemotherapy agents
83,84
.  Also, ABT-263 has been shown to increase the efficacy of the 
kinesin-5 inhibitor, paclitaxel, and the MAP kinase (MEK) inhibitor, G-963
85,86
.  Currently, 
several phase II clinical trials are investigating the combination of ABT-263 in lymphoid cancers 
and solid tumors (http://clinicaltrials.gov). 
  In order to resolve the dose-limiting toxicity of ABT-263, ABT-199 (navitoclax) was 
designed to selectively target Bcl-2. ABT-199 potently inhibits Bcl-2 function and inhibits 
growth of Bcl-2 dependent tumors in vivo and spares human platelets. In three patients with 
refractory CLL a single dose of ABT-199 resulted in tumor lysis within 24 hours
68
. However, on 
target tumor lysis syndrome (TLS) has been observed in a subset of patients treated with ABT-
199 and thus dosing regiments must be tailored to mitigate this risk
87
. Despite the dose-limiting 
toxicity of ABT-199, the drug has been successful in phase I trials in patients with refractory or 
relapsed CLL or non-Hodgkin lymphoma
68
. Phase II clinical trials are ongoing to investigate 
combination treatment with ABT-199 (http://clinicaltrials.gov). 
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  Numerous in vitro studies have investigated the role of the Bcl-2 family in resistance to 
Bcl-2 family inhibitors.  Multiple studies performed with ABT-737/ABT-263 acquired resistant 
cell lines show increased levels of anti-apoptotic proteins Mcl-1 and Bfl-1/A1, which are not 
targeted by ABT-737
88-91
.  Acute myeloid leukemia cell lines with high expression of Mcl-1 are 
resistant to ABT-737
88
.  Investigations performed with lymphoma cell lines with acquired 
resistance to ABT-737 also observed an upregulation of Mcl-1 and Bfl-1/A1
89
. All of the in vitro 
studies have lead to similar findings: the upregulation of Mcl-1 confers resistance to Bcl-2/Bcl-
xL inhibitors.  As with any in vitro study there is always the same question: how does this 
correlate to whole living organisms? Is there a different phenotype for resistance to Bcl-2/Bcl-xL 
inhibitors in vivo?   
 
Other Mechanisms of Cancer Drug Resistance 
 Drug resistance due to defects and/or inhibition of the apoptosis pathway has been 
discussed so far; however it is important to discuss other mechanisms of resistance.  One of the 
more common mechanisms of resistance to a broad range of anticancer drugs is what is known as 
multidrug resistance.  Multidrug resistance is simultaneous resistance to several structurally 
unrelated drugs that do not share a common mechanism of action.  Different types of cellular 
multidrug resistance have been described; however the general mechanism involves expression 
of ATP-dependent efflux pumps
92
. The transporters known as ATP-binding cassette (ABC) 
transporters are able to efflux drugs out of the tumor cell or reduce drug uptake into the cell.  The 
protein encoded by the multidrug resistant (MDR1) gene is P-glycoprotein (Pgp), which is one of 
the most thoroughly studied ABC proteins
93,94
.  MDR1/P-gp (ABCB1) functions as an energy 
dependent plasma membrane efflux pump that actively transports drugs out of cells. Cancers 
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such as acute myeloid leukemia (AML), breast cancer and small-cell lung cancer show higher 
expression levels of MDR/P-gp after chemotherapy
95
.  Not all multidrug resistant cells express 
MDR1/P-gp, which lead to the discovery of the multidrug resistant associated protein 1 (MRP1 
or ABCC1)
96
.  The discovery of MRP1 instigated the search for homologs, which lead to the 
discovery of eight additional members of the ABCC subfamily of transporters
97
.  Overexpression 
of MRP1 in tumor cells confers resistance to drugs such as anthracyclines, vinca alkaloids, and 
methotrexate
98
.  Studies in human cancer cell lines selected for mitoxantrone resistance resulted 
in the discovery of another member of the ABC transporters
99,100
.  This transporter (ABCG2) is 
known as the breast cancer resistance protein (BCRP).  Multidrug resistance remains a challenge 
to successful treatment of cancer. 
 Drug inactivation is yet another complex mechanism employed in living systems that 
results in drug resistance. Interactions between a drug and different proteins in vivo can modify, 
partially degrade, or complex the drug with other molecules or proteins leading to drug 
activation. Cancer cells can develop resistance by decreasing drug activation due to the fact that 
several cancer therapies must undergo metabolic activation in order to achieve clinical 
efficacy
101,102
. Examples of drug activation and inactivation include the cytochrome P450 (CYP) 
system, glutathione-S-transferase (GST) superfamily and uridine diphospho-
glucuronosyltransferase (UGT) superfamily
1,103
. An example of where decreased drug activation 
results in resistance, is observed in the treatment of acute myeloid leukemia with cytarabine 
(AraC), a nucleoside drug
104
. Activation of AraC requires several phosphorylation events that 
convert the drug to AraC-triphosphate. Drug resistance to AraC results when down regulation or 
mutation in the metabolic pathway, specifically deoxycitidine kinase, develops
104,105
.  
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 For several years, DNA damaging agents were highly effective drugs for the treatment of 
cancer
106
. However, the repair of damaged DNA has been found to play a prominent role in 
anticancer drug resistance. The DNA damage response mechanism can reverse the drug induced 
damage resulting from treatment with drugs that directly or indirectly damage DNA. An example 
of this phenomenon has been observed in resistance that results from use of cisplatin, a platinum 
containing drug resulting in harmful DNA crosslinks leading to apoptosis
107
. Several resistance 
mechanisms to platinum containing drugs have been identified including inactivation by 
glutathione and other thiol containing proteins as well as increased DNA repair
108
. Nucleotide 
excision repair, a key player in the development of resistance to platinum-based drugs, is mainly 
responsible for repairing bulky DNA adducts such as those resulting from interaction with 
cisplatin
109
.  Homologous recombination is another form of DNA repair associated with 
reversing platinum-based drug damage
109,110
. Taken together, the efficacy of platinum-based 
drugs depends on the cancer cells ability to evade activation of DNA damage response 
mechanisms. 
 Although genetic alterations in tumor cells play a key role in tumor development and 
resistance mechanisms, the microenvironment including the extracellular matrix and tumor 
vasculature hold an integral part in the progression of the disease and the development of 
resistance
3,111-114
.  Examples of resistant mechanisms involving the tumor microenvironment 
include cell-adhesion mediated resistance and the secretion of soluble growth factors or 
cytokines
3,115
.  Cell-adhesion mediated resistance has resulted in response to many therapeutics, 
including chemotherapy and targeted therapies
116,117
. Stromal derived hepatocyte growth factor 
(HGF) has been shown to result in resistance to BRAF inhibition in BRAF mutant melanoma 
cells by increased phosphorylation of the HGF receptor MET
118
.  Patients with increased 
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expression of HGF exhibited reduced response to BRAF inhibitor treatment
118
. These studies 
further support that the interaction between a tumor cell and its microenvironment is important to 
determine mechanisms of resistance to drug therapies. Unfortunately, resistance mechanisms to 
cancer drugs are commonly investigated utilizing cell lines that develop resistance in vitro absent 
from environmental factors.  Thus, in vitro development of drug resistance may not be an 
accurate representation of the resistance mechanisms that will arise in a clinical setting. 
Furthermore, drug exposure to cancer cells in in vitro conditions does not account for the 
pharmacokinetics involved in drug treatment in a whole animal
119,120
. Taken together, it is 
necessary to investigate mechanisms of resistance that develop in vivo in order to more 
accurately understand what will result in human patients. 
 
Treatment Strategies 
 A major shift has begun in the treatment of cancer from a standardized regiment of 
chemotherapy drugs for specific cancers to one where the underlying molecular mechanism and 
oncogenic target of individual tumors are considered in order to best treat patients. The number 
and diversity of cancer drug resistance mechanisms highlights the need for rational treatment 
strategies aimed at avoiding and overcoming drug resistance. Combination and sequential use of 
therapies has been stated as the best treatment options to overcome cancer drug resistance
121-124
. 
Combination treatment strategies should be more effective than single agent treatment because 
targeting multiple pathways at once can lead to a synergistic cell death response and certain 
drugs may sensitize drug resistant cancer cells to other drugs
125-128
. For example, pretreatment 
with histone deacetylase and methylation inhibitors in cisplatin resistant ovarian cancer cells re-
sensitized these cells to cell death by cisplatin
125
. Gefitinib, a BCRP inhibitor, reversed resistance 
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to anticancer agents in breast cancer cells by inhibiting drug efflux, subsequently the 
combination of gefitinib and irenotecan resulted in increased survival in vivo compared to single 
agent treatment
129
. In a study performed with p53 mutant pancreatic tumor cells the  combination 
of AZD7762 (checkpoint kinase 1 inhibitor) and olaparib (PARP1 inhibitor) sensitized the cells 
to radiation treatment
123
. These studies and several others emphasize the potential benefit of 
combination and/or sequential treatment regimens for treating resistant or relapsed cancers. 
 Combination and sequential treatment strategies also address the fact that cancer cell 
populations are heterogeneous. Recent studies show that a fraction of cells within the 
heterogeneous population possess drug resistance prior to treatment
130-133
. For example, a study 
in acute myeloid leukemia (AML) identified two clones, one sensitive to drug treatment and the 
other resistant to drug treatment
130
. By definition, drug treatment of cancers results in the death 
of drug sensitive cancer cells, thus the drug resistant fraction of cancer cells can survive and 
expand resulting in the relapse of cancer. This possibility could exist in all forms of cancer. 
However, it is also possible for cancers to be less heterogeneous than others. In a clonal 
composition study of breast cancer both monogenomic and polygenomic tumors were 
identified
132
. The polygenomic tumors may contain different types of clonal subpopulations, all 
of which could have varying degrees of sensitivity or resistance to drug treatment. 
 Combination studies using MDM2-p53 interaction inhibitors and Bcl-2/Bcl-xL inhibitors 
has the added advantage of inducing p53 target genes leading to apoptosis and cell cycle arrest 
along with inhibition of highly expressed antiapoptotic Bcl-2 family members, Bcl-2 and Bcl-xL.  
Further inhibition of antiapoptotic Bcl-2 proteins can be achieved by successful inhibition of 
MDM2 resulting in activation of p53 and an increase in PUMA, which has been shown to 
antagonize Mcl-1
16
.  Less frequent dosing and decreased drug dosage of the drugs could both 
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delay the onset of resistance and result in less toxicity in patients. In cancers where Bcl-2 is 
overexpressed and p53 wild-type status is retained, the targeted combination therapy of Bcl-2 
and MDM2-p53 interaction inhibitors investigated in this dissertation constitute a mechanism-
based therapy with considerable clinical potential. Overall, these studies suggest that 
combination and/or sequential treatment of cancers is an attractive treatment strategy and should 
be further investigated. 
 
Aims 
 The treatment of cancer has improved greatly over the last several decades, mainly due to 
the development of highly efficacious chemotherapeutics and targeted therapies.  However, the 
ability of cancer cells to develop resistance to drug treatment remains a significant impediment to 
successful cancer treatment.  Numerous investigations have identified a myriad of mechanisms 
in which cancer cells can elude drug therapy, and it has become evident that resistance exists 
against every effective drug.  The determination of the mechanisms of drug resistance can help 
elucidate valuable information about how to circumvent drug resistance in cancer cells. 
Targeting key apoptosis regulators such as the MDM2-p53 interaction and the commonly 
overexpressed Bcl-2 protein, is an exciting, new therapeutic strategy for reactivating apoptosis in 
cancer cells that have acquired resistance to cell death
45,134,135
.  To date, non-peptide small 
molecule Bcl-2 inhibitors and MDM2-p53 interaction inhibitors have been developed and 
several such inhibitors have been advanced into clinical trials
75,136,137
. While such small-molecule 
drugs have shown promise in initial clinical trials, it is fully expected that cancer cells will 
acquire resistance to these novel anticancer agents
138
. 
The overall aims of my dissertation are as follows: 
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1. To investigate the mechanisms of resistance in cancer to MDM2-p53 interaction 
inhibitors and Bcl-2/Bcl-xL inhibitors both in vitro and in vivo. 
2. To identify rationale treatment strategies aimed at overcoming and circumventing 
resistance in order to increase tumor-free survival. 
3. To address differences in the development of resistance to MDM2-p53 interaction 
inhibitors and Bcl-2/Bcl-xL inhibitors both in vitro and in vivo. 
  
 22 
References 
1. Housman, G. et al. Drug resistance in cancer: an overview. Cancers (Basel) 6, 1769-92 (2014). 
2. DeVita, V.T., Hellman, S. & Rosenberg, S.A. Cancer, principles & practice of oncology, lxxv, 2898 
p. (Lippincott Williams & Wilkins, Philadelphia, PA, 2005). 
3. Ramos, P. & Bentires-Alj, M. Mechanism-based cancer therapy: resistance to therapy, therapy 
for resistance. Oncogene (2014). 
4. Lane, D.P. & Crawford, L.V. T antigen is bound to a host protein in SV40-transformed cells. 
Nature 278, 261-3 (1979). 
5. Vogelstein, B., Lane, D. & Levine, A.J. Surfing the p53 network. Nature 408, 307-10 (2000). 
6. Malkin, D. et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and 
other neoplasms. Science 250, 1233-8 (1990). 
7. Donehower, L.A. et al. Mice deficient for p53 are developmentally normal but susceptible to 
spontaneous tumours. Nature 356, 215-21 (1992). 
8. Hainaut, P. & Hollstein, M. p53 and human cancer: the first ten thousand mutations. Adv Cancer 
Res 77, 81-137 (2000). 
9. Chene, P. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat Rev 
Cancer 3, 102-9 (2003). 
10. Laptenko, O. & Prives, C. Transcriptional regulation by p53: one protein, many possibilities. Cell 
Death Differ 13, 951-61 (2006). 
11. Wu, X., Bayle, J.H., Olson, D. & Levine, A.J. The p53-mdm-2 autoregulatory feedback loop. Genes 
Dev 7, 1126-32 (1993). 
12. Freedman, D.A., Wu, L. & Levine, A.J. Functions of the MDM2 oncoprotein. Cell Mol Life Sci 55, 
96-107 (1999). 
13. Vousden, K.H. & Lu, X. Live or let die: the cell's response to p53. Nat Rev Cancer 2, 594-604 
(2002). 
14. Green, D.R. Apoptotic pathways: the roads to ruin. Cell 94, 695-8 (1998). 
15. Amaral, J.D., Xavier, J.M., Steer, C.J. & Rodrigues, C.M. The role of p53 in apoptosis. Discov Med 
9, 145-52 (2010). 
16. Shibue, T. et al. Differential contribution of Puma and Noxa in dual regulation of p53-mediated 
apoptotic pathways. EMBO J 25, 4952-62 (2006). 
17. Jeffers, J.R. et al. Puma is an essential mediator of p53-dependent and -independent apoptotic 
pathways. Cancer Cell 4, 321-8 (2003). 
18. Chen, L. et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows 
complementary apoptotic function. Mol Cell 17, 393-403 (2005). 
19. Oda, E. et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-
induced apoptosis. Science 288, 1053-8 (2000). 
20. Sax, J.K. et al. BID regulation by p53 contributes to chemosensitivity. Nat Cell Biol 4, 842-9 
(2002). 
21. Miyashita, T. et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro 
and in vivo. Oncogene 9, 1799-805 (1994). 
22. Mihara, M. et al. p53 has a direct apoptogenic role at the mitochondria. Mol Cell 11, 577-90 
(2003). 
23. Lane, D.P. Cancer. p53, guardian of the genome. Nature 358, 15-6 (1992). 
24. el-Deiry, W.S. et al. WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-25 
(1993). 
25. Levine, A.J. p53, the cellular gatekeeper for growth and division. Cell 88, 323-31 (1997). 
 23 
26. Bates, S. & Vousden, K.H. p53 in signaling checkpoint arrest or apoptosis. Curr Opin Genet Dev 6, 
12-8 (1996). 
27. Sax, J.K. & El-Deiry, W.S. p53 downstream targets and chemosensitivity. Cell Death Differ 10, 
413-7 (2003). 
28. Joerger, A.C. & Fersht, A.R. Structural biology of the tumor suppressor p53. Annu Rev Biochem 
77, 557-82 (2008). 
29. Bullock, A.N. & Fersht, A.R. Rescuing the function of mutant p53. Nat Rev Cancer 1, 68-76 
(2001). 
30. Brosh, R. & Rotter, V. When mutants gain new powers: news from the mutant p53 field. Nat Rev 
Cancer 9, 701-13 (2009). 
31. Fakharzadeh, S.S., Trusko, S.P. & George, D.L. Tumorigenic potential associated with enhanced 
expression of a gene that is amplified in a mouse tumor cell line. EMBO J 10, 1565-9 (1991). 
32. Wade, M., Li, Y.C. & Wahl, G.M. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat 
Rev Cancer 13, 83-96 (2013). 
33. Momand, J., Zambetti, G.P., Olson, D.C., George, D. & Levine, A.J. The mdm-2 oncogene product 
forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69, 1237-
45 (1992). 
34. Shangary, S. & Wang, S. Targeting the MDM2-p53 interaction for cancer therapy. Clin Cancer Res 
14, 5318-24 (2008). 
35. Montes de Oca Luna, R., Wagner, D.S. & Lozano, G. Rescue of early embryonic lethality in 
mdm2-deficient mice by deletion of p53. Nature 378, 203-6 (1995). 
36. Weber, J.D., Taylor, L.J., Roussel, M.F., Sherr, C.J. & Bar-Sagi, D. Nucleolar Arf sequesters Mdm2 
and activates p53. Nat Cell Biol 1, 20-6 (1999). 
37. Kussie, P.H. et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor 
transactivation domain. Science 274, 948-53 (1996). 
38. Vassilev, L.T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of 
MDM2. Science 303, 844-8 (2004). 
39. Tovar, C. et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: 
implications for therapy. Proc Natl Acad Sci U S A 103, 1888-93 (2006). 
40. Tovar, C. et al. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses 
human tumors in preclinical cancer models. Cancer Res 73, 2587-97 (2013). 
41. Vu, B. et al. Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development. 
ACS Med Chem Lett 4, 466-9 (2013). 
42. Ray-Coquard, I. et al. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients 
with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory 
proof-of-mechanism study. Lancet Oncol 13, 1133-40 (2012). 
43. Shangary, S. et al. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to 
tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci U S A 105, 3933-8 
(2008). 
44. Wang, S. et al. SAR405838: An optimized inhibitor of MDM2-p53 interaction that induces 
complete and durable tumor regression. Cancer Res (2014). 
45. Danial, N.N. & Korsmeyer, S.J. Cell death: critical control points. Cell 116, 205-19 (2004). 
46. Green, D.R. & Kroemer, G. The pathophysiology of mitochondrial cell death. Science 305, 626-9 
(2004). 
47. Chao, D.T. & Korsmeyer, S.J. BCL-2 family: regulators of cell death. Annu Rev Immunol 16, 395-
419 (1998). 
48. Reed, J.C. Bcl-2 family proteins: strategies for overcoming chemoresistance in cancer. Adv 
Pharmacol 41, 501-32 (1997). 
 24 
49. Letai, A.G. Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat Rev Cancer 8, 
121-32 (2008). 
50. Cory, S. & Adams, J.M. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev 
Cancer 2, 647-56 (2002). 
51. Gross, A., McDonnell, J.M. & Korsmeyer, S.J. BCL-2 family members and the mitochondria in 
apoptosis. Genes Dev 13, 1899-911 (1999). 
52. Cragg, M.S., Harris, C., Strasser, A. & Scott, C.L. Unleashing the power of inhibitors of oncogenic 
kinases through BH3 mimetics. Nat Rev Cancer 9, 321-6 (2009). 
53. Martinou, J.C. & Youle, R.J. Mitochondria in apoptosis: Bcl-2 family members and mitochondrial 
dynamics. Dev Cell 21, 92-101 (2011). 
54. Cheng, E.H. et al. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and 
BAK-mediated mitochondrial apoptosis. Mol Cell 8, 705-11 (2001). 
55. Knudson, C.M., Tung, K.S., Tourtellotte, W.G., Brown, G.A. & Korsmeyer, S.J. Bax-deficient mice 
with lymphoid hyperplasia and male germ cell death. Science 270, 96-9 (1995). 
56. Wei, M.C. et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction 
and death. Science 292, 727-30 (2001). 
57. Wang, C. & Youle, R.J. Predominant requirement of Bax for apoptosis in HCT116 cells is 
determined by Mcl-1's inhibitory effect on Bak. Oncogene (2011). 
58. Kojima, K. et al. Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a 
small molecule BCL-2 antagonist ABT-737. Cancer (2011). 
59. Cheng, E.H., Sheiko, T.V., Fisher, J.K., Craigen, W.J. & Korsmeyer, S.J. VDAC2 inhibits BAK 
activation and mitochondrial apoptosis. Science 301, 513-7 (2003). 
60. Gallenne, T. et al. Bax activation by the BH3-only protein Puma promotes cell dependence on 
antiapoptotic Bcl-2 family members. J Cell Biol 185, 279-90 (2009). 
61. Willis, S.N. et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until 
displaced by BH3-only proteins. Genes Dev 19, 1294-305 (2005). 
62. Certo, M. et al. Mitochondria primed by death signals determine cellular addiction to 
antiapoptotic BCL-2 family members. Cancer Cell 9, 351-65 (2006). 
63. Ni Chonghaile, T. et al. Pretreatment mitochondrial priming correlates with clinical response to 
cytotoxic chemotherapy. Science 334, 1129-33 (2011). 
64. Sarosiek, K.A., Ni Chonghaile, T. & Letai, A. Mitochondria: gatekeepers of response to 
chemotherapy. Trends Cell Biol 23, 612-9 (2013). 
65. Ni Chonghaile, T. & Letai, A. Mimicking the BH3 domain to kill cancer cells. Oncogene 27 Suppl 1, 
S149-57 (2008). 
66. Tse, C. et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 68, 
3421-8 (2008). 
67. Oltersdorf, T. et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. 
Nature 435, 677-81 (2005). 
68. Souers, A.J. et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity 
while sparing platelets. Nat Med 19, 202-8 (2013). 
69. Liu, G. et al. An open-label, multicenter, phase I/II study of single-agent AT-101 in men with 
castrate-resistant prostate cancer. Clin Cancer Res 15, 3172-6 (2009). 
70. Wu, D. An overview of the clinical pharmacology and therapeutic potential of gossypol as a male 
contraceptive agent and in gynaecological disease. Drugs 38, 333-41 (1989). 
71. Kitada, S. et al. Discovery, characterization, and structure-activity relationships studies of 
proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J Med Chem 46, 
4259-64 (2003). 
 25 
72. Meng, Y. et al. Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-
xL inhibition accompanied by increase of Puma and Noxa. Mol Cancer Ther 7, 2192-202 (2008). 
73. Balakrishnan, K., Wierda, W.G., Keating, M.J. & Gandhi, V. Gossypol, a BH3 mimetic, induces 
apoptosis in chronic lymphocytic leukemia cells. Blood 112, 1971-80 (2008). 
74. Tahir, S.K. et al. Influence of Bcl-2 family members on the cellular response of small-cell lung 
cancer cell lines to ABT-737. Cancer Res 67, 1176-83 (2007). 
75. Roberts, A.W. et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: 
results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin 
Oncol 30, 488-96 (2012). 
76. Wilson, W.H. et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid 
malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, 
and antitumour activity. Lancet Oncol 11, 1149-59 (2010). 
77. Gandhi, L. et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients 
with small-cell lung cancer and other solid tumors. J Clin Oncol 29, 909-16 (2011). 
78. Schoenwaelder, S.M. et al. Bcl-xL-inhibitory BH3 mimetics can induce a transient 
thrombocytopathy that undermines the hemostatic function of platelets. Blood 118, 1663-74 
(2011). 
79. Zhang, H. et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ 14, 943-
51 (2007). 
80. Rudin, C.M. et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in 
patients with relapsed small cell lung cancer. Clin Cancer Res 18, 3163-9 (2012). 
81. Trudel, S. et al. The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity 
and shows synergistic effect with dexamethasone and melphalan. Clin Cancer Res 13, 621-9 
(2007). 
82. Romani, A.A. et al. The BH3-mimetic ABT-737 targets the apoptotic machinery in 
cholangiocarcinoma cell lines resulting in synergistic interactions with zoledronic acid. Cancer 
Chemother Pharmacol 67, 557-67 (2011). 
83. Kang, M.H. et al. Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic 
leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood 110, 2057-66 
(2007). 
84. Ackler, S. et al. The Bcl-2 inhibitor ABT-263 enhances the response of multiple 
chemotherapeutic regimens in hematologic tumors in vivo. Cancer Chemother Pharmacol 66, 
869-80 (2010). 
85. Shi, J., Zhou, Y., Huang, H.C. & Mitchison, T.J. Navitoclax (ABT-263) accelerates apoptosis during 
drug-induced mitotic arrest by antagonizing Bcl-xL. Cancer Res 71, 4518-26 (2011). 
86. Tan, N. et al. Bcl-2/Bcl-xL inhibition increases the efficacy of MEK inhibition alone and in 
combination with PI3 kinase inhibition in lung and pancreatic tumor models. Mol Cancer Ther 
12, 853-64 (2013). 
87. Ng, S.Y. & Davids, M.S. Selective Bcl-2 inhibition to treat chronic lymphocytic leukemia and non-
Hodgkin lymphoma. Clin Adv Hematol Oncol 12, 224-9 (2014). 
88. Konopleva, M. et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic 
ABT-737 in acute myeloid leukemia. Cancer Cell 10, 375-88 (2006). 
89. Yecies, D., Carlson, N.E., Deng, J. & Letai, A. Acquired resistance to ABT-737 in lymphoma cells 
that up-regulate MCL-1 and BFL-1. Blood 115, 3304-13 (2010). 
90. Deng, J. et al. BH3 profiling identifies three distinct classes of apoptotic blocks to predict 
response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell 12, 171-85 (2007). 
91. van Delft, M.F. et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently 
induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10, 389-99 (2006). 
 26 
92. Gottesman, M.M., Fojo, T. & Bates, S.E. Multidrug resistance in cancer: role of ATP-dependent 
transporters. Nat Rev Cancer 2, 48-58 (2002). 
93. Ueda, K., Cardarelli, C., Gottesman, M.M. & Pastan, I. Expression of a full-length cDNA for the 
human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl 
Acad Sci U S A 84, 3004-8 (1987). 
94. Fojo, A.T. et al. Expression of a multidrug-resistance gene in human tumors and tissues. Proc 
Natl Acad Sci U S A 84, 265-9 (1987). 
95. Shaffer, B.C. et al. Drug resistance: still a daunting challenge to the successful treatment of AML. 
Drug Resist Updat 15, 62-9 (2012). 
96. Cole, S.P. et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer 
cell line. Science 258, 1650-4 (1992). 
97. Borst, P., Evers, R., Kool, M. & Wijnholds, J. A family of drug transporters: the multidrug 
resistance-associated proteins. J Natl Cancer Inst 92, 1295-302 (2000). 
98. Gillet, J.P., Efferth, T. & Remacle, J. Chemotherapy-induced resistance by ATP-binding cassette 
transporter genes. Biochim Biophys Acta 1775, 237-62 (2007). 
99. Miyake, K. et al. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-
resistant cells: demonstration of homology to ABC transport genes. Cancer Res 59, 8-13 (1999). 
100. Doyle, L.A. et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc 
Natl Acad Sci U S A 95, 15665-70 (1998). 
101. Rochat, B. Importance of influx and efflux systems and xenobiotic metabolizing enzymes in 
intratumoral disposition of anticancer agents. Curr Cancer Drug Targets 9, 652-74 (2009). 
102. Zahreddine, H. & Borden, K.L. Mechanisms and insights into drug resistance in cancer. Front 
Pharmacol 4, 28 (2013). 
103. Michael, M. & Doherty, M.M. Tumoral drug metabolism: overview and its implications for 
cancer therapy. J Clin Oncol 23, 205-29 (2005). 
104. Sampath, D. et al. Pharmacodynamics of cytarabine alone and in combination with 7-
hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood 107, 2517-
24 (2006). 
105. Cai, J. et al. Two distinct molecular mechanisms underlying cytarabine resistance in human 
leukemic cells. Cancer Res 68, 2349-57 (2008). 
106. Gurova, K. New hopes from old drugs: revisiting DNA-binding small molecules as anticancer 
agents. Future Oncol 5, 1685-704 (2009). 
107. Chu, G. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J Biol 
Chem 269, 787-90 (1994). 
108. Galluzzi, L. et al. Molecular mechanisms of cisplatin resistance. Oncogene 31, 1869-83 (2012). 
109. Bonanno, L., Favaretto, A. & Rosell, R. Platinum drugs and DNA repair mechanisms in lung 
cancer. Anticancer Res 34, 493-501 (2014). 
110. Olaussen, K.A. et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based 
adjuvant chemotherapy. N Engl J Med 355, 983-91 (2006). 
111. Meads, M.B., Gatenby, R.A. & Dalton, W.S. Environment-mediated drug resistance: a major 
contributor to minimal residual disease. Nat Rev Cancer 9, 665-74 (2009). 
112. Junttila, M.R. & de Sauvage, F.J. Influence of tumour micro-environment heterogeneity on 
therapeutic response. Nature 501, 346-54 (2013). 
113. Joyce, J.A. & Pollard, J.W. Microenvironmental regulation of metastasis. Nat Rev Cancer 9, 239-
52 (2009). 
114. Teicher, B.A. et al. Tumor resistance to alkylating agents conferred by mechanisms operative 
only in vivo. Science 247, 1457-61 (1990). 
 27 
115. Wilson, T.R. et al. Widespread potential for growth-factor-driven resistance to anticancer kinase 
inhibitors. Nature 487, 505-9 (2012). 
116. Huang, C. et al. beta1 integrin mediates an alternative survival pathway in breast cancer cells 
resistant to lapatinib. Breast Cancer Res 13, R84 (2011). 
117. Muranen, T. et al. Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached 
cancer cells. Cancer Cell 21, 227-39 (2012). 
118. Straussman, R. et al. Tumour micro-environment elicits innate resistance to RAF inhibitors 
through HGF secretion. Nature 487, 500-4 (2012). 
119. Goodman, L.S., Gilman, A., Brunton, L.L., Lazo, J.S. & Parker, K.L. Goodman & Gilman's the 
pharmacological basis of therapeutics, xxiii, 2021 p. (McGraw-Hill, New York, 2006). 
120. Peterson, J.K. & Houghton, P.J. Integrating pharmacology and in vivo cancer models in preclinical 
and clinical drug development. Eur J Cancer 40, 837-44 (2004). 
121. Byler, S. et al. Genetic and epigenetic aspects of breast cancer progression and therapy. 
Anticancer Res 34, 1071-7 (2014). 
122. Sarkar, S., Goldgar, S., Byler, S., Rosenthal, S. & Heerboth, S. Demethylation and re-expression of 
epigenetically silenced tumor suppressor genes: sensitization of cancer cells by combination 
therapy. Epigenomics 5, 87-94 (2013). 
123. Vance, S. et al. Selective radiosensitization of p53 mutant pancreatic cancer cells by combined 
inhibition of Chk1 and PARP1. Cell Cycle 10, 4321-9 (2011). 
124. Shi, H., Kong, X., Ribas, A. & Lo, R.S. Combinatorial treatments that overcome PDGFRbeta-driven 
resistance of melanoma cells to V600EB-RAF inhibition. Cancer Res 71, 5067-74 (2011). 
125. Cacan, E., Ali, M.W., Boyd, N.H., Hooks, S.B. & Greer, S.F. Inhibition of HDAC1 and DNMT1 
modulate RGS10 expression and decrease ovarian cancer chemoresistance. PLoS One 9, e87455 
(2014). 
126. Juergens, R.A. et al. Combination epigenetic therapy has efficacy in patients with refractory 
advanced non-small cell lung cancer. Cancer Discov 1, 598-607 (2011). 
127. Sarkar, S. et al. Histone deacetylase inhibitors reverse CpG methylation by regulating DNMT1 
through ERK signaling. Anticancer Res 31, 2723-32 (2011). 
128. Johannessen, C.M. et al. A melanocyte lineage program confers resistance to MAP kinase 
pathway inhibition. Nature 504, 138-42 (2013). 
129. Yanase, K. et al. Gefitinib reverses breast cancer resistance protein-mediated drug resistance. 
Mol Cancer Ther 3, 1119-25 (2004). 
130. Parkin, B. et al. Clonal evolution and devolution after chemotherapy in adult acute myelogenous 
leukemia. Blood 121, 369-77 (2013). 
131. Lapidot, T. et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID 
mice. Nature 367, 645-8 (1994). 
132. Navin, N. et al. Inferring tumor progression from genomic heterogeneity. Genome Res 20, 68-80 
(2010). 
133. Campbell, P.J. et al. The patterns and dynamics of genomic instability in metastatic pancreatic 
cancer. Nature 467, 1109-13 (2010). 
134. Hanahan, D. & Weinberg, R.A. The hallmarks of cancer. Cell 100, 57-70 (2000). 
135. Campos, L. et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated 
with poor response to chemotherapy. Blood 81, 3091-6 (1993). 
136. Vassilev, L.T. p53 Activation by small molecules: application in oncology. J Med Chem 48, 4491-9 
(2005). 
137. Saddler, C. et al. Comprehensive biomarker and genomic analysis identifies p53 status as the 
major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. Blood 111, 
1584-93 (2008). 
 28 
138. Gottesman, M.M. Mechanisms of cancer drug resistance. Annu Rev Med 53, 615-27 (2002). 
 
 29 
Chapter 2  
Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors 
in Acute Leukemia In Vitro and In Vivo 
 
Abstract 
 Acquired resistance of tumors to anticancer therapies is a major clinical concern. We 
have investigated the acquired resistance mechanisms in vitro and in vivo in acute leukemia 
models for two novel anticancer drugs in clinical development, the MDM2-p53 interaction 
inhibitor SAR405838 and the dual Bcl-2/Bcl-xL inhibitor ABT-263. Both drugs are highly 
effective in induction of apoptosis in the ALL RS4;11 cell line in vitro and in the xenograft 
tissue and achieve complete RS4;11 xenograft tumor regression in mice. However, resistance 
develops for both drugs in vitro and in vivo. Analysis of the regrown tumors showed that the 
RS4;11 tumor cells acquire resistance to SAR405838 by mutation of p53 gene or compromised 
p53 function and to ABT-263 through down-regulation of pro-apoptotic Bcl-2 family member 
BAX. In vitro and in vivo, RS4;11 cells that become resistance to SAR405838 retain sensitivity 
to ABT-263 and conversely, RS4;11 cells that develop resistance to ABT-263 also retain 
sensitivity to SAR405838. Sequential treatment of RS4;11 xenografts with ABT-263 followed 
by SAR405838 led to a longer tumor free survival than either single agent. Combination of 
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SAR405838 and ABT-263 achieved longer term tumor regression without signs of toxicity than 
either agent alone. Our study provides new insights into the resistant mechanisms for Bcl-2/Bcl-
xL and MDM2 inhibitors in acute leukemia and suggests that sequential or combination 
treatment of these two distinct classes of apoptosis-inducing agents should be explored as a new 
treatment strategy for acute leukemia with the goal of overcoming acquired drug resistance and 
improving long-term clinical outcome for patients. 
 
Introduction 
 Leukemias such as acute lymphoblastic leukemia (ALL) and acute myeloid leukemia 
(AML), remain incurable with conventional chemotherapy and new therapeutic strategies are 
urgently needed
1,2
. Since resistance to apoptosis is a hallmark of cancers, including leukemia, 
targeting key apoptosis regulators with the goal of overcoming apoptosis resistance in tumor 
cells has been pursued as a promising cancer therapeutic approach
3
.  
 Bcl-2 family proteins are a class of master regulators of apoptosis
4-8
. The original 
member of the family, Bcl-2 is overexpressed in patients with leukemia and is an attractive 
therapeutic target
9,10
. Intense research efforts have yielded potent small-molecule Bcl-2 
inhibitors such as ABT-737 
11
 and its orally active analogue ABT-263 (navitoclax)
12
. Both ABT-
737 and ABT-263 bind to Bcl-2, Bcl-xL and Bcl-w with very high affinities, but it has been 
shown that Bcl-2, but not Bcl-xL or Bcl-w, is the most critical target for these compounds in 
leukemia cells in vivo
13
. In this study we refer to these compounds as Bcl-2 inhibitors. In both 
preclinical and clinical trials, these ABT compounds have shown impressive activity as single 
agents against leukemia
11,12,14
.  
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 The tumor suppressor p53 represents another attractive therapeutic target for leukemia
15-
20
. In about 90% of leukemias, p53 retains its wild-type status, but its function is effectively 
inhibited by its endogenous cellular antagonist MDM2
21-25
. As a consequence, MDM2 inhibitors, 
small molecules designed to block the p53-MDM2 protein-protein interaction can activate wild-
type p53
26-29
. Nutlin-3 is the first potent, specific, bona fide MDM2 inhibitor 
29
 and its analogue, 
RG7112, has been advanced into clinical development
30
. In preclinical studies, RG7112 is 
capable of inducing tumor regression in xenograft models of leukemia in mice
31
 and is being 
tested in clinical trials in leukemia. In addition to RG7112, six other highly potent MDM2 
inhibitors, including SAR405838 designed in our laboratory, are now in clinical trials for cancer 
treatment
32
. 
 Despite impressive initial antitumor activity, the complete tumor regression achieved by 
ABT-737/ABT-263
12
  and RG7112
31
 in xenograft models of leukemia was transitory; tumors 
eventually regrew after the treatments were terminated, suggesting emergence of resistance to 
both classes of drugs. Indeed, acquired resistance is, in general, a major cause of cancer drug 
failure in clinical trials 
33
. Although resistance mechanisms for Bcl-2 and MDM2 inhibitors have 
been investigated in cell culture models
34-38
, no study has been performed to investigate the 
acquired resistance mechanisms in vivo. In the present study, we have elucidated resistant 
mechanisms for both classes of apoptosis-inducing drugs in vitro and in vivo using the RS4;11 
acute lymphoblastic leukemia cell line and the MV4;11 acute myeloid leukemia cell line.  
 To investigate resistance mechanisms for Bcl-2 inhibitors, we have employed ABT-737 
and ABT-263, which bind to Bcl-2, Bcl-xL and Bcl-w with high affinities and show high 
specificity over Mcl-1 and A1 proteins. ABT-737 and ABT-263 have the same mechanism of 
action in apoptosis induction in tumor cells
5,11,12
 and the orally active ABT-263 is currently in 
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Phase I/II clinical trials for cancer treatment. To investigate resistant mechanisms for MDM2 
inhibitors, we employed SAR405838. SAR405838 binds to MDM2 with a Ki value of 0.88 nM, 
has a very high specificity over other proteins, and is capable of inducing complete tumor 
regression in multiple models.  SAR405838 has progressed into Phase I clinical trials for cancer 
treatment. 
 In this study, we have elucidated acquired resistance mechanisms for these two classes of 
apoptosis-inducing drugs in vitro and in vivo using the RS4;11 ALL and the MV4;11 AML cell 
lines. This has yielded insights into the resistance mechanisms for both classes of drugs and has 
led to the development of new therapeutic strategies which deliver longer tumor-free survival in 
mice. 
Materials and Methods 
Reagents and antibodies. SAR405838 was synthesized using the same method
39
.  ABT-263 and 
ABT-737 were purchased from Selleck Chemicals (Houston, TX).  Rabbit antibodies for 
caspase-3, PARP, Mcl-1 (D35A5), Bcl-xL (54H6) and mouse antibody for caspase-7 were 
obtained from Cell Signaling Technology (Danvers, MA); rabbit antibodies for GAPDH and 
BAK (G-23) and mouse antibodies for BAX (6A7 and 6D149) and Bcl-2 were from Santa Cruz 
Biotechnology (Dallas, TX); mouse antibody p53 (Ab-6) and MDM2 (Ab-1) and rabbit PUMA 
(Ab-1) were from Calbiochem (Millipore). Mouse antibody for p21 was from BD Pharminogen 
(San Jose, CA). 
 
Cell Culture, cell viability, and apoptosis assays. RS4;11 and MV4;11 cell lines were 
purchased from American Type Culture Collection and cultured as recommended. Cell viability 
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was evaluated by a WST-8 assay (Dojindo)
40
. Apoptosis was analyzed using Annexin V-FLUOS 
staining kit (Roche Applied Science, Indianapolis, IN). Differences in mean values of cell 
apoptosis among different groups were analyzed by 2-way ANOVA using Prism, with a P value 
of <0.05 being considered significant. 
 
Resistant Cell Lines. RS4;11 and MV4;11 parental cell lines were treated with ABT-737 
starting from 10 nM for 72 hrs. The cells were then rinsed and the remaining live cells were 
expanded in normal medium. This process was repeated with increased drug concentration till 10 
μM and surviving cells were utilized for subsequent experiments. An identical protocol was 
utilized to obtain in vitro sublines resistant to SAR405838, with the exception of the final drug 
concentration being  0 μM  DMSO treated cell lines were generated for use as control. 
 
Stable short hairpin interfering RNA constructs. Short 19-bp hairpins for generating RNA 
interference: BAX (nucleotides 239-257, Genbank NM138761), BAK (nucleotides 535-553, 
Genbank NM001188) and p53 (nucleotides 611-629 Genbank NM000546)
35
. The 
oligonucleotides were annealed and ligated into a self-inactivating lentiviral vector under the 
control of the H1 promoter 
41
.  The vector also carried the GFP reporter gene under control of the 
human ubiquitin-C promoter to monitor infection efficiency. A scrambled shRNA construct was 
utilized as a control
35
.  Lentiviral shRNA virus-containing supernatant, generated by the 
University of Michigan Vector Core, was used to infect RS4;11 and MV4;11 cells. At 96 h post 
infection the cells were sorted for GFP fluorescence. 
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p53 Mutation analysis. Primers to amplify and sequence genomic DNA for exons 2 to 11 of 
human p53 were used according to Hauser et al.
2
.  Primers to amplify and sequence cDNA for 
exons 2 to 11 of human p53 were used according to Aziz et al.
36
.  Mutation surveyor 
(SoftGenetics LLC) software was used to compare experimental sequences against Refseq 
GenBank as well as by visual inspection of sequence tracings. 
 
In vivo xenograft studies. To develop xenograft tumors, 5 x 10
6 
tumor cells with 50% Matrigel 
were injected subcutaneously on the dorsal side of SCID mice. All groups had 6-12 mice unless 
otherwise stated. Tumor sizes and animal weights were measured 2-3 times per week with tumor 
volume (mm
3
) = (length x width
2
)/2. Significance (P) was calculated by unpaired two-tailed t 
test using Prism.  P value of < 0.05 being considered significant. 
 
Synergy studies. Synergism, additive effects and antagonism was assessed using the Chou-
Talalay
42
 method and Calcusyn software (Biosoft, Ferguson, MO). The effect on cell growth was 
expressed as a fraction of cells that were killed by the single agent treatment compared to the 
combination treatment versus untreated cells utilizing the WST-8 assay at 4 days. The effect on 
apoptosis was determined using flow cytometry in order to identify the percentage of Annexin 
V-positive cells in the single agent treatment compared to the combination treatment versus 
control treated cells at 24 h for RS4;11 cells and 48 h for MV4;11 cells.  
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Results 
Establishment and characterization of RS4;11 sublines resistant in vitro and in vivo to 
ABT-263/ABT-737 
 The acute lymphoblastic leukemia RS4;11 cell line has a t(4;11) chromosomal 
rearrangement and has been shown in vitro and in vivo to be sensitive to ABT-737/ABT-263
12,43
. 
 Treatment of RS4;11 xenograft tumors in mice with ABT-737 results in complete tumor 
regression (Fig. 2.1A), but all tumors regrow shortly after termination of the treatment. We 
isolated RS4;11 tumor cells from the regrown tumors and established 8 sublines (G3M1-G3M8). 
While the RS4;11 parental cell line and 2 representative sublines (30L and 30R) established from 
the vehicle- treated tumors  are highly sensitive in a cell growth assay to both ABT-737 and 
ABT-263, all 8 sublines obtained from the ABT-737 treated tumors have increased resistance to 
ABT-263 and ABT-737, with an average IC50 value >100-fold higher than the control cell lines 
(Fig. 2.1B and SI Fig. S2.1B). Apoptosis analysis by flow cytometry confirmed that these 
sublines (G3M1-G3M8) are indeed highly resistant to ABT-737 and ABT-263 (Fig. 2.1C and SI 
Fig. S2.1C). 
 In previous studies, upregulation of the Mcl-1 protein was shown to be a primary 
mechanism for acquired resistance of tumor cells to ABT-737
34,35
. Western blotting, however, 
showed that the highly resistant sublines (G3M1-G3M8) and the sensitive control cell lines have 
similar levels of Mcl-1 expression (Fig. 2.1G). Profiling of other Bcl-2 family members showed 
that compared to the control cell lines, BAX protein, but not its homolog BAK, is consistently 
and profoundly down-regulated in all the 8 resistant cell lines (Fig. 2.1F). However, in 
comparison to the control cell lines, other Bcl-2 protein levels are not significantly different in 
these resistant sublines (G3M1-G3M8) (Fig. 2.1F and SI Fig. S2.1A). 
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 To investigate the acquisition of resistance to the Bcl-2 inhibitors of the RS4;11 cell line 
in vitro, the RS4;11 cells were exposed to gradually increasing concentrations (10 nM gradually 
increasing to 10 µM) of ABT-737.  This yielded two sublines (ABTR1 and ABTR2) which, in a 
cell growth assay exhibit >100-fold resistance to ABT-263 compared to the parental RS4;11 cell 
line (Fig. 2.1D). This resistance of the ABTR1 and ABTR2 sublines to ABT-263 was further 
confirmed in an apoptosis assay (Fig. 2.1E). Western blotting showed that the BAX protein, but 
not BAK, is profoundly down-regulated in ABTR1 and ABTR2 sublines when compared to the 
parental cell line, similar to what was observed in the 8 in vivo cell lines (Fig. 2.1G). However, 
in contrast to the lack of Mcl-1 upregulation in all the 8 in vivo sublines, Mcl-1 is clearly 
upregulated in the ABTR sublines when compared to the control cell lines (Fig. 2.1G). 
 
Figure 2.1 Establishment and characterization of in vitro and in vivo RS4;11 sublines 
resistant to ABT-263/ABT-737.   
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A, Establishment of in vivo RS4;11 sublines. RS4;11 xenograft tumors were treated with vehicle 
(grey) or ABT-737 at 100 mg/kg, i.p. for 5 days per week for 2 weeks (black). Vehicle treated 
tumors and ABT-737-treated, regrown tumors were harvested and cultured to generate sublines. 
B, Sensitivity of in vivo RS4;11 sublines to ABT-263 in a cell growth assay. Parental, two 
representative vehicle-treated sublines (30L and 30R) and 8 sublines (G3M1-G3M8) generated 
from ABT-treated tumors were treated with ABT-263 or vehicle control for 4 days for cell 
viability analysis using a WST assay. C, Sensitivity of in vivo RS4;11 sublines to ABT-263 in an 
apoptosis assay. Parental RS4;11 cell line and one representative subline from vehicle-treated 
tumors, two representative sublines from ABT-treated tumors (G3M2 and G3M7) were treated 
with ABT-263 or  vehicle control for 24 h for apoptosis analysis by flow cytometry with 
Annexin V/P.I. double staining. Data (mean ± SD) are from triplicates, including both early 
(Annexin V-positive/PI-negative) and late (Annexin V-positive/PI-positive) apoptotic cells. D, 
Sensitivity of in vitro RS4;11 sublines to ABT-263 in a cell growth assay using the same 
protocol as in (B). E, Sensitivity of in vitro RS4;11 sublines to ABT-263 in an apoptosis assay 
using the same protocol as in (C). F and G, Immunoblotting of Bcl-2 family proteins for in vitro 
and in vivo RS4;11 resistant sublines and control lines. GAPDH was used as the loading control. 
 
Establishment and characterization of in vitro and in vivo RS4;11 resistant sublines to the 
MDM2 inhibitor SAR405838 
 The MDM2 inhibitor SAR405838 effectively inhibits cell growth with IC50 = 140 nM 
(Fig. 2.2B) and induces apoptosis in the RS4;11 cell line, which has wild-type p53 status (Fig. 
2.2C). 
 In vivo, treatment of the RS4;11 xenograft tumors in mice with SAR405838 induces rapid 
and complete tumor regression, which persists for >30 days, but eventually the tumors return 
(Fig. 2.2A). Harvesting and culturing all tumors regrown after treatment with SAR405838 
established 7 sublines (G7M1-G7M7).  A cell growth assay showed that while two sublines, 
G7M2 and G7M4, exhibit 5-fold greater resistance to SAR405838 compared with the parental 
and vehicle treated cell lines, the other 5 sublines show an average of >35-fold increased 
resistance to SAR405838 (Fig. 2.2B). The moderate resistance to SAR405838 in the G7M4 
subline and more significant resistance in the G7M1 and G7M7 sublines were confirmed in an 
apoptosis assay (Fig. 2.2C and SI Fig. S2.2A). 
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 We also established two RS4;11 sublines (MIR1 and MIR2) in vitro by gradually 
increasing the concentration of SAR405838 in the cell culture. Both the MIR1 and MIR2 
sublines exhibit >60-fold greater resistance to SAR405838 in a cell growth assay compared with 
the control cell lines (Fig. 2.2D) and their profound resistance was confirmed in an apoptosis 
assay (Fig. 2.2E). 
 The activity of SAR405838 depends upon wild-type p53
32
, and consequently we 
analyzed the p53 mutation by sequencing exons 2-11 in all the in vitro and in vivo sublines 
obtained after the SAR405838 treatment (SI Table S2.1). Both the MIR1 and MIR2 in vitro 
sublines and 5 out of 7 of the in vivo sublines were found to harbor p53 mutation(s). 
 Immunoblotting showed that, compared to the control cell lines, basal p53 protein 
expression is increased in all the sublines harboring p53 mutation(s) (G7M1-3, 6-7 and MIR1-2) 
(Fig. 2.2F). In contrast to the loss of BAX expression in the resistant sublines obtained from the 
ABT-737/ABT-263 treatment, similar levels of BAX protein were found in all the sublines 
obtained from treatment with SAR405838 and in the parental cell line (Fig. 2.2F). 
 To investigate if any of these sublines obtained from treatment with SAR405838 still 
retained functional p53, we examined induction by SAR405838 treatment of two p53-regulated 
proteins, p21 and MDM2, and also accumulation of p53 protein and PARP cleavage in these 
sublines (SI Fig. S2.2B and C). No significant induction of p21 protein, PARP cleavage or p53 
accumulation is observed in the sublines harboring p53 mutation (G7M1, G7M3 and G7M7) 
when treated with SAR405838, indicative of the absence of p53 activation (SI Fig. S2.2B). In the 
G7M4 subline lacking p53 mutation, SAR405838 induces a dose-dependent increase of p21 and 
p53 proteins and cleavage of PARP, indicative of p53 activation and apoptosis induction, but 
with a reduced potency as compared to that in the parental cell line (SI Fig. S2C). In G7M5, 
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which has no expression of p53 at the basal level (Fig. 2.2F), SAR405838 fails to induce p53 and 
p21 upregulation and PARP cleavage, indicative of non-functional p53 (SI Fig. S2.2C). 
 
Figure 2.2 Establishment and characterization of RS4;11 sublines obtained from in vitro 
and in vivo treatment with SAR405838. 
A, Establishment of in vivo RS4;11 sublines. RS4;11 xenograft tumors were treated with vehicle 
(grey) or 200 mg/kg of SAR405838 orally for 21 days and SAR405838-treated tumors (G7M1-
G7M7) were harvested when the regressed tumors regrew to approximately 100 mm
3
 and then 
cultured to establish sublines. B, Sensitivity of in vivo RS4;11 sublines to SAR405838 in a cell 
growth assay. Parental RS4;11 cell line and sublines established from RS4;11 xenografts (30L, 
vehicle-treated; G7M1-G7M7, SAR405838-treated) were treated with SAR405838 for 4 days for 
cell viability analysis in a WST assay. C, Sensitivity of in vivo RS4;11 sublines to SAR405838 in 
an apoptosis assay. Parental RS4;11 cell line and sublines established from representative 
RS4;11 xenografts were treated with SAR405838 for 24 h for apoptosis analysis by flow 
cytometry with Annexin V/P.I. double staining. D, Sensitivity of in vitro RS4;11 sublines to 
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SAR405838 in a cell growth assay using the same protocol as in (B). E, Sensitivity of in vitro 
RS4;11 sublines to SAR405838 in an apoptosis assay using the same protocol as in (C). F, 
Immunoblotting of representative Bcl-2 family proteins and p53 for in vitro and in vivo RS4;11 
sublines and control lines, with GAPDH as the loading control. 
  
 Taken together, these data show that treatment of the RS4;11 cell line in vitro and in vivo 
by SAR405838 yielded SAR405838-resistant sublines, which have either inactive, mutated p53 
or p53 with compromised function. 
 
RS4;11 sublines resistant to Bcl-2 inhibitors retain their sensitivity to MDM2 inhibitor  
 Exons 2-11 were sequenced for each of the RS4;11 in vitro and in vivo sublines resistant 
to ABT compounds. No p53 mutation could be detected, suggesting that these sublines retain 
wild-type p53 status and sensitivity to MDM2 inhibitors. 
 SAR405838 effectively inhibits cell growth in the ABTR1 and ABTR2 in vitro sublines 
(Fig. 2.3A) and induces dose-dependent apoptosis in the ABTR1 and ABTR2 sublines, albeit 
with modestly reduced potency compared to that in the control RS4;11 cell line (Fig. 2.3B). 
 In the 8 in vivo sublines (G3M1-G3M8) that developed profound resistance to ABT 
compounds, SAR405838 is still very effective in inhibition of cell growth (Fig. 2.3C). Apoptosis 
induction by SAR405838 is attenuated by a factor of only 2-3 in the G3M1 and G3M6 sublines 
compared to the RS4;11 parental and vehicle-treated cell lines (Fig. 2.3D). In the RS4;11 
parental, and the G3M1 and G3M6 sublines, SAR405838 effectively and dose-dependently 
induces both activation of p53 and apoptosis, as shown by upregulation of p53, p21, MDM2 and 
PUMA proteins, and cleavage of caspase-3, caspase-7 and PARP (Fig. 2.3E). 
 41 
 Hence, when the RS4;11 cells develop profound acquired resistance to Bcl-2 inhibitors 
ABT-737 and ABT-263, they are still sensitive to the MDM2 inhibitor SAR405838, and lack 
cross-resistance. 
 
 
Figure 2.3 Evaluation of SAR405838 in RS4;11 sublines obtained from in vitro or in vivo 
treatment with ABT-737. 
A and C, RS4;11 parental and sublines were treated for 4 days with SAR405838 for cell viability 
analysis by a WST assay. B and D, RS4;11 parental and representative sublines were treated 
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with SAR405838 for 24 h for apoptosis analysis by flow cytometry with Annexin V/P.I. double 
staining. E, RS4;11 parental and two representative sublines were treated with SAR405838 for 
24 h for immunoblotting of p53 and p53-regulated proteins and biochemical markers of 
apoptosis. F, Regrown RS4;11 xenografts treated with ABT-263 for daily, 21 days at 100 mg/kg 
via oral gavage were retreated with either SAR405838 at 100 mg/kg (solid lines) or ABT-263 
(dashed lines) at 150 mg/kg, both via oral gavage, daily for 14 days. Data are presented as 
percent change of the tumor volume for each mouse. 
 
RS4;11 sublines resistant to SAR405838 retain sensitivity to ABT-263 
 We next evaluated ABT-263 for its effectiveness in the RS4;11 sublines obtained by the 
treatment with SAR405838. In cell growth and apoptosis assays, both in vitro (MIR1 and MIR2) 
and in vivo (G7M1-G7M7) sublines show sensitivity to ABT-263 similar to that of the RS4;11 
control cell lines (Fig. 2.4A-D). Based upon western blot analysis of cleavage of caspase-3, 
caspase-7 and PARP (Fig. 2.4E), ABT-263 is equally effective in induction of apoptosis in 
representative sublines such as G7M1, G7M4 and G7M7 (Fig. 4D). Hence, while p53 mutation 
or compromised p53 function greatly diminishes the activity of the MDM2 inhibitor 
SAR405838, it has no effect on the activity of the Bcl-2 inhibitor ABT-263. 
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Figure 2.4 Evaluation of ABT-263 in RS4;11 sublines obtained from in vitro or in vivo 
treatment with SAR405838. 
A and C, Cells were treated with ABT-263 for 4 days and cell viability was determined by a 
WST assay. B and D, Cells were treated with ABT-263 for 24 h for apoptosis analysis by flow 
cytometry with Annexin V/P.I. double staining. E, Representative RS4;11 sublines were treated 
with ABT-263 for 24 h and biochemical markers of apoptosis were analyzed by immunoblotting. 
F, Antitumor activity of ABT-263 and SAR405838 in regrown tumors initially treated with 
SAR405838. When regressed tumors initially treated with SAR405838 regrew to 100-200 mm
3
, 
they were treated with either ABT-263 at 100 mg/kg (dashed lines), or SAR405838 (solid lines) 
at 200 mg/kg for 14 days. Data are presented as percent change of the tumor volume for each 
mouse. 
 
Regrown tumors resistant to the initial drug are responsive to the second class of drug in 
mice  
 Although RS4;11 cells acquire resistance to Bcl-2 inhibitors ABT-263/ABT-737, they 
retain their sensitivity to the MDM2 inhibitor SAR405838 in vitro (Fig. 2.3A-E). Conversely, 
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when the RS4;11 cells acquire resistance to SAR405838, they remain sensitive to ABT-263 in 
vitro (Fig. 2.4A-E). These data suggest that although the RS4;11 tumors acquire resistance to one 
class of apoptosis-inducing agent, they may still be susceptible in vivo to a second class of 
apoptosis-inducing agents. We directly examined this possibility in mice bearing the RS4;11 
xenograft tumors. 
 When RS4;11 xenograft tumors are treated with ABT-263, all tumors rapidly become 
undetectable (SI Fig. S2.3A) but regrow shortly after the treatment is ended. When the regrown 
tumors reached an average volume of 200 mm
3
, they were randomized into two groups and 
treated with either the maximum tolerated dose of ABT-263 (150 mg/kg) or 100 mg/kg of 
SAR405838 (Fig. 2.3F and SI Fig. S2.3C). While one of the 4 tumors treated with ABT-263 
regressed, the other three tumors showed no regression (Fig. 2.3F), in contrast to the rapid tumor 
regression observed following the initial treatment with ABT-263 at 100 mg/kg. In comparison, 
all 4 regrown tumors treated with SAR405838 experienced rapid and complete regression (Fig. 
2.3F). 
 Similarly, treatment with SAR405838 at 100 mg/kg results in rapid and complete 
regression of RS4;11 tumors in mice (SI Fig. S2.4A), but all tumors regrow after termination of 
the treatment. When the regrown tumors reached an average volume of 200 mm
3
, they were 
randomized into two groups and treated with either ABT-263 at 100 mg/kg or SAR405838 at 
200 mg/kg (Fig. 2.4F), levels at which there was no sign of toxicity (SI Fig. S2.4C). All tumors 
treated with SAR405838 at 200 mg/kg continued to grow, but 5 out of 6 tumors treated with 
ABT-263 rapidly regressed (Fig. 2.4F). All cell lines isolated from tumors treated with ABT-263 
at any point in either treatment protocol showed loss of BAX protein expression, while the 
expression of the BAK protein was not altered (SI Fig. S2.3B and S2.4B). 
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 Taken together, these in vivo data clearly showed that when regrown xenograft tumors 
become resistant to the initial class of drug, they are still very responsive to the second class of 
drug, and lack cross-resistance. 
 
Different roles of BAX in the activity of Bcl-2 and MDM2 inhibitors 
 When the parental RS4;11 cell line was treated with ABT-737/ABT-263 in vitro and in 
vivo, BAX, but not BAK is significantly down-regulated (Fig. 2.1F-G). Although becoming 
highly resistant to ABT compounds, the cells retain their sensitivity to SAR405838 (Fig. 2.3). 
This suggests that BAX and BAK may play different roles in the activity of these two different 
classes of apoptosis-inducing drugs. Consequently, we further investigated the role of BAX and 
BAK in cell growth inhibition and apoptosis induction assays for these two classes of drugs. 
 Efficient knock-down of BAX expression using lenti-virus shRNA in the RS4;11 parental 
cell line renders the cells >100-times less sensitive to ABT-263 in a cell growth assay and 
unresponsive to apoptosis induction by ABT-263 (Fig. 2.5A-C). However, efficient shRNA 
knock-down of BAK expression in the RS4;11 parental cell line has little or no effect on the 
activity of ABT-263 in both cell growth and apoptosis assays (Fig. 2.5A-C). For SAR405838, 
efficient knock-down of BAX expression in the RS4;11 parental cell line results in only a ~3-
fold reduction in sensitivity (Fig. 2.5D) and efficient knock-down of BAK expression has no 
effect on the activity of SAR405838 (Fig. 2.5D). 
 Since BAX was profoundly down-regulated in all the RS4;11 sublines obtained from in 
vitro and in vivo treatment of ABT-737/ABT-263 (Fig. 2.1, SI Fig. S2.3B, S2.4B), we knocked 
down BAK in one of the sublines (G3M1) (Fig. 2.5A) and evaluated the sensitivity of the cells to 
SAR405838.  Efficient knock-down of BAK in the G3M1 subline results in a >15-fold increase 
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in the IC50 value for SAR405838 in the cell growth assay and significantly reduces the apoptotic 
response to SAR405838 (Fig. 2.5D and E). 
 
 
Figure 2.5 Investigation of the role of BAK, BAX and p53 in the activity of ABT-263 and 
SAR405838 in the RS4;11 cell line.   
A, Immunoblots illustrating the efficiency of the shRNA-lentiviral approach in RS4;11 and 
RS4;11/G3M1 cells. B and C, BAX or BAK was knocked down by shRNA in the RS4;11 
parental cell line and cells were treated with ABT-263 for 4 days for cell viability analysis by a 
WST assay (B), or treated with ABT-263 for 24 h for apoptosis analysis by flow cytometry with 
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Annexin V/P.I. double staining (C) (***, P <0.001; ****, P <0.0001; t test). D, BAK or BAX 
was efficiently knocked down by shRNA in the RS4;11 parental cell line or BAK was knocked 
down in G3M1 subline with a very low level of BAX. Cells were treated with SAR405838 for 4 
days for cell viability analysis using a WST assay. E, Apoptosis analysis by flow cytometry with 
Annexin V/P.I. double staining. RS4;11/shControl, G3M1/shControl and G3M1/shBAK cells 
were treated with SAR405838 for 24 h (*, P <0.05; **, P <0.01; t test). F and G, p53 was 
knocked down by shRNA in the RS4;11 parental cell line and the cells were treated with ABT-
263 for 4 days for cell viability analysis in a WST assay (F), or for 24 h for apoptosis analysis by 
flow cytometry with Annexin V/P.I. double staining (G). 
 
 These data show that while BAX, but not BAK, plays a dominant role in mediating the 
activity of Bcl-2 inhibitor ABT-263 in the RS4;11 cell line, the presence of either BAX or BAK 
is sufficient for effective apoptosis induction by the MDM2 inhibitor SAR405838. Absence of 
both BAX and BAK, however, renders the cells resistant to SAR405838. 
 
p53 has a minimal role in the activity of Bcl-2 inhibitors 
 ABT-263 is very effective in RS4;11 sublines harboring mutated p53, suggesting that p53 
has a minimal role in the activity of Bcl-2 inhibitors. To further examine this, we stably knocked 
down p53 in the RS4;11 parental cell line using lenti-virus shRNA (Fig. 2.5A). While efficient 
knock-down of p53 dramatically reduces the activity of SAR405838
32
, it has only a modest 
effect on the activity of ABT-263 (Fig. 2.5F and G) and we concluded that p53 has a minimal 
role in the activity of Bcl-2 inhibitors in the RS4;11 cell line. 
 
Lack of cross-resistance for MDM2 and Bcl-2 inhibitors in the MV4;11 acute leukemia cell 
line  
 We next extended our studies to the MV4;11 acute leukemia cell line, which also harbors 
a t4;11 chromosomal translocation. 
 First, we generated resistant sublines to SAR405838 and ABT-263. The MV.ABT-R cell 
line, generated by treating the MV4;11 cell line with ABT-263 in vitro, is >18-fold less sensitive 
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to ABT-263 than the control cell lines, but retains its sensitivity to SAR405838 (SI Fig. S2.5). 
Interestingly, western blot analysis reveals that while the MV.ABT-R subline shows no decrease 
in expression of BAX, it has increased expression of Mcl-1 protein compared to controls (SI Fig. 
S2.5C). However, stable knock-down of BAX expression in parental MV4;11 cells drastically 
attenuates cell growth inhibition and apoptosis induction by ABT-263 compared to the control 
cell line, but remains sensitive to SAR405838 (SI Fig. S2.6).  In comparison, efficient knock-
down of BAK expression in the parental MV4;11 cells has little to no effect on the activity of 
ABT-263 or SAR405838 (SI Fig. S2.6). 
 Similarly, the MV.MI-R cell line, generated by treating the MV4;11 cell line with 
SAR405838 in vitro, becomes >20-times less sensitive to SAR405838 than the control cell line 
in a cell growth assay but has the same sensitivity as the parental cell line to ABT-263 (SI Fig. 
S2.5). Sequencing exons 2-11 revealed that p53 has undergone a homozygous mutation, R248W, 
in the MV.MI-R cell line. To further test the role of p53 on the activity of ABT-263 and 
SAR405838, we stably knocked down p53 in the MV4;11 cell line (SI Fig. S2.7A). While 
efficient knock-down of p53 greatly reduces the activity of SAR405838, it has no effect on the 
activity of ABT-263 (SI Fig. S2.7B-D).  
 We next evaluated both SAR405838 and ABT-263 in mice bearing MV4;11 xenograft 
tumors. Although ABT-263 is fairly potent in vitro, it only inhibits tumor growth modestly in 
vivo at 100 mg/kg (SI Fig. 2.8A).  In comparison, SAR405838 at 100 mg/kg induces rapid and 
complete, but transient tumor regression in 100% of mice bearing MV4;11 xenograft tumors (SI 
Fig. S2.8A). When regressed tumors treated with SAR405838 regrew, they were harvested and 
cultured to establish 6 sublines (G3M1-G3M6). Two representative tumors treated with vehicle 
were also harvested and cultured yielding two sublines (G1M3 and G1M7). A cell growth assay 
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showed that while two sublines (G3M2 and G3M5) exhibit moderate resistance to SAR405838 
compared with the parental and vehicle treated cell lines, the other 4 sublines (G3M1, G3M3, 
G3M4 and G3M6) are highly resistant to SAR405838 (SI Fig. S2.8B). SAR405838 becomes 
ineffective in activation of apoptosis and p53 in these highly resistant sublines (SI Fig. S2.8C 
and D). Sequencing exons 2-11 showed that p53 has a homozygous mutation, R248W, in all of 
the highly resistant SAR405838 sublines. In comparison, p53 has a heterozygous mutation at 
R248W in the moderately resistant sublines. MV4;11 in vivo sublines resistant to SAR405838 
are still sensitive to ABT-263 in both cell growth and apoptosis assays and exhibit little or no 
resistance, compared to control cell lines (SI Fig. S2.9). 
 
Sequential and Combination treatment strategies improve 100% tumor-free survival 
 Although both Bcl-2 and MDM2 inhibitors used as single agents achieve rapid and 
complete regression of the RS4;11 xenograft tumors, tumors regrow shortly after cessation of the 
treatment. To determine the synergistic effects on cell growth and induction of apoptosis we 
combined ABT-263 and SAR405838 using a fixed-ratio experimental design. Our data 
showed that the combination of ABT-263 and SAR405838 in the RS4;11 and MV4;11 cell lines 
is highly synergistic based upon the combination index (CI) values (50) (SI Tables S2.2 and 
S2.3). Based upon the encouraging in vitro combination data, we investigated strategies with the 
goal of improving tumor-free survival of mice in the RS4;11 tumor xenograft model. 
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Figure 2.6 Antitumor activity of ABT-263 and SAR405838 alone, sequential treatment of 
the two drugs and their combination in the RS4;11 and MV4;11 xenografts models. 
A, Antitumor activity of single agents and sequential treatment in the RS4;11 xenograft model. 
Mice were treated via oral gavage with vehicle, ABT-263 or SAR405838 for 14 days, or with 
one drug for 7 days, immediately followed with the other drug for another 7 days. B, Antitumor 
activity of ABT-263, SAR405838 and their combination in the RS4;11 xenograft model. When 
tumors grew to approximately 300 mm
3
, mice were treated with vehicle, ABT-263, SAR405838 
or their combination at 50 mg/kg for 14 days via oral gavage. C, Percentage of tumor-free 
survival of mice in the RS4;11 efficacy experiment shown in (B). D, Antitumor activity of single 
agents and sequential treatment in MV4;11 xenograft model. Mice were treated via oral gavage 
with vehicle, ABT-263 or SAR405838 for 18 days, or with one drug for 9 days, immediately 
followed with the other drug for another 9 days. E, Antitumor activity of ABT-263, SAR405838 
and their combination in the MV4;11 xenograft model. When tumors grew to approximately 200 
mm
3
, mice were treated with vehicle, ABT-263, SAR405838 or their combination at 50 mg/kg of 
ABT-263 and 100 mg/kg of SAR405838 twice weekly for 18 days via oral gavage. F, Percentage 
of tumor-free survival of mice in the RS4;11 efficacy experiment shown in (E). 
 
 We tested two sequential treatment strategies in vivo: (1) ABT-263 daily for one week 
first followed by SAR405838 daily for another week or (2) SAR405838 daily for one week first 
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followed by ABT-263 daily for another week (Fig. 2.6A). Both strategies showed no signs of 
toxicity (SI Fig. S2.10A). The 100% tumor-free survival time was 12 days in the SAR405838 
single-agent, daily treatment for 2 weeks and 24 days in the ABT-263 single-agent, daily 
treatment for 2 weeks. In comparison, the 100% tumor-free survival time was 41 days for the 
sequential treatment scheme of ABT-263 first for one week, followed by SAR405838 for another 
week, and 24 days for the reverse sequential treatment scheme (Fig. 2.6A). Hence, the sequential 
treatment with, first ABT-263, followed by SAR405838 is the most effective of the four 
treatment schemes in achieving tumor-free survival in 100% of mice. 
 Using a fixed-ratio experimental design, we assessed whether the combination of the Bcl-
2/Bcl-xL inhibitor (ABT-263) and MDM2-p53 interaction inhibitor (SAR405838) would work in 
tandem to elicit a synergistic response in acute leukemia.  Interaction studies between ABT-263 
and SAR405838 showed synergistic effects on cell growth (SI Table S2.2) and induction of 
apoptosis (SI Table S2.3) in both RS4;11 and MV4;11 cells. The combination index (CI) values 
for cell growth and apoptosis were under 1.0 for both cell lines, suggesting a synergistic effect 
between ABT-263 and SAR405838. 
 We also tested whether the combination of ABT-263 and SAR405838 results in a longer 
tumor free survival than single agents. The MTD for the combination was determined to be 50 
mg/kg for each agent in RS4;11 tumor-bearing mice. SAR405838 as a single agent at 50 mg/kg 
does not yield complete tumor regression in any animal, but ABT-263 as a single agent at 50 
mg/kg achieves tumor regression in 4 out of 6 mice. The combination results in complete tumor 
regression in 100% of mice for a period of 44 days (Fig. 2.6B and C) with no sign of toxicity (SI 
Fig. S2.10B). Therefore, the combination of these two drugs at 50 mg/kg each is effective in 
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achieving and maintaining complete tumor regression in 100% of mice for a sustained period of 
time. 
 
Strategies to improve tumor-free survival in mice bearing MV4;11 tumors 
 We next evaluated strategies with the goal of improving tumor-free survival in mice 
bearing MV4;11 tumors. 
 Although ABT-263 shows minimal in vivo anticancer activity when used as a single 
agent, either sequential treatment protocol (ABT-263 followed by SAR405838, or the reverse) 
results in tumor regression. Interestingly, the sequential treatment protocol, ABT-263 first then 
SAR405838, yields longer tumor regression than the reverse treatment protocol (Fig. 2.6D). The 
rapid regression upon treatment with SAR405838 after ABT-263 suggests that MV4;11 tumors 
treated with ABT-263 alone fail to develop resistance to SAR405838 in vivo. The combination 
of ABT-263 and SAR405838 both at 100 mg/kg is toxic in MV4;11 tumor-bearing mice, but the 
combination of ABT-263 at 50 mg/kg and SAR405838 at 100 mg/kg is well tolerated (SI Fig. 
S2.10C). While SAR405838 at 100 mg/kg for 18 days achieves complete tumor regression in 
100% of mice for an average of 7 days, the combination of ABT-263 at 50 mg/kg and 
SAR405838 at 100 mg/kg with a less frequent dosing-schedule (twice a week for 3 weeks) 
achieves and maintains complete tumor regression in 100% of mice for an average of 14 days 
(Fig. 2.6E and F). 
Discussion 
 Although a number of recently developed targeted anticancer drugs are highly effective 
in achieving complete response in the clinic, such responses are typically short-lived and patients 
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relapse quickly
1,44,45
. Therefore, it is critical to identify mechanism(s) of acquired resistance and 
to develop rational strategies to combat such resistance with the goal of improving the outcome 
of patients with the disease. In the present study, we elucidated the mechanisms of acquired 
resistance of two classes of apoptosis-inducing agents, the Bcl-2 inhibitors ABT-737/ABT-263 
and the MDM2 inhibitor SAR405838 in two acute leukemia models in vitro and in vivo. 
  ABT-737 and ABT-263 are highly effective in inducing apoptosis in the RS4;11 cell line 
in vitro, achieving complete regression of RS4;11 xenograft tumors in mice, but both in vitro and 
in vivo treatments lead to the development of sublines that have profound acquired resistance to 
this class of drugs. BAX, but not BAK, is consistently down-regulated in each of these resistant 
sublines obtained from in vitro and in vivo treatments, suggesting a critical role for BAX (Fig. 
2.1F, 2.1G, SI Fig. S2.3 and S2.4). Indeed, knock-down of BAX, but not BAK, in the parental 
RS4;11 cell line dramatically reduces the sensitivity of the tumor cells to ABT-737/ABT-263, 
confirming that BAX, but not BAK, is a key mediator for apoptosis induction by these Bcl-2 
inhibitors (Fig. 2.5). Interestingly, while Mcl-1 is not upregulated in those resistant sublines 
obtained from in vivo treatment of RS4;11 tumors in mice with ABT-737, it is greatly increased 
in those resistant sublines obtained from in vitro treatment of ABT-737. One critical difference is 
that in in vitro treatment, the drug is present at a constant concentration and poses a continuous 
high threat to the survival of tumor cells.  For in vivo treatment, the pressure from the drug for 
tumor cell survival fluctuates, as a result of the pharmacokinetic effect. Therefore, while both in 
vitro and in vivo treatments of the RS4;11 cell line with these Bcl-2 inhibitors result in acquired 
resistance, the precise mechanisms whereby resistance is acquired are subtly different. While 
Mcl-1 upregulation has been shown to be a primary mechanism of resistance to ABT-737/ABT-
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263, our study shows that loss of BAX, but not upregulation of Mcl-1, is the primary resistant 
mechanism when the RS4;11 tumors are treated with ABT-737 in animals
34,35
. 
 Similarly, in vitro and in vivo treatments of the RS4;11 cell line with the MDM2 inhibitor 
SAR405838 also result in acquired resistance. Our analyses showed that each of these resistant 
sublines harbors either an inactivating mutated p53 gene for its transcriptional activity or 
contains p53 with compromised transcriptional activity. As a result, in these resistant sublines 
with defective p53, SAR405838 is either completely ineffective or much less effective in 
activation of p53. 
 It is of great interest that all RS4;11 sublines obtained from in vitro and in vivo treatments 
with either ABT-737 or ABT-263, while becoming highly resistant to ABT compounds, retain 
their sensitivity to the MDM2 inhibitor SAR405838 in vitro (Fig. 2.3). Significantly, when 
regressed RS4;11 tumors treated with ABT-263 at 100 mg/kg regrow, they become much less 
responsive to even a higher dose of ABT-263 (150 mg/kg,  the MTD) but undergo rapid tumor 
regression when treated with the MDM2 inhibitor SAR405838 (Fig. 2.3F). Similarly, ABT-263 
is still very effective against RS4;11 resistant sublines generated with both in vitro and in vivo 
treatment of SAR405838 in both cell growth inhibition and apoptosis assays (Fig. 2.4). 
Furthermore, when RS4;11 tumors initially treated with SAR405838 regrow, they become 
unresponsive to the second round of SAR405838 treatment but undergo rapid tumor regression 
when treated with ABT-263 (Fig. 2.4F). Hence, our results show that because RS4;11 tumor 
cells develop different acquired resistant mechanisms to MDM2 and Bcl-2 inhibitors, tumors 
cells that become highly resistant to one class of drug retain their sensitivity to the second class 
of drug in vitro. Importantly, regrown tumors that are unresponsive to the initial drug in mice 
still undergo rapid tumor regression when treated with the second class of drug. 
 55 
 The lack of cross-resistance of the RS4;11 acute leukemia cells to Bcl-2 and MDM2 
inhibitors suggests that p53 and BAX play different roles in the activities of these two classes of 
apoptosis-inducing agents. Efficient knock-down of p53 in the parental RS4;11 cell line 
significantly diminishes the activity of SAR405838 but has a minimal effect on the activity of 
ABT-263 (Fig. 2.5). Conversely, efficient knock-down of BAX has a profound effect in reducing 
the potency of ABT-263, but only has a modest effect on the activity of SAR405838. 
Interestingly, knock-down of BAK has no effect on the activity for both SAR405838 and ABT-
263. However, down-regulation of BAK in a RS4;11 subline, which already has an undetectable 
level of BAX, results in resistance to apoptosis induction by SAR405838. These results suggest 
that presence of either BAK or BAX is sufficient for induction of apoptosis by MDM2 inhibitors 
(Fig. 2.5). 
 Since both ABT-263 and SAR405838 can completely regress the RS4;11 tumors in mice 
and all the cell lines cultured from relapsed tumors lack cross-resistance to these two classes of 
drugs, we tested two sequential and one combination treatment strategies for their effectiveness 
in achieving tumor-free survival. Sequential treatment with ABT-263 100 mg/kg daily for a 
week, followed by SAR405838 100 mg/kg daily for another week, can achieve 71% longer 
tumor-free survival in 100% of mice (41 days) than ABT-263 as a single agent daily for 2 weeks 
at the same dose (24 days) and 240% longer than SAR405838 used as a single agent daily for 2 
weeks at the same dose (12 days) (Fig. 2.6A). The alternative sequential treatment is only 
equally effective, as compared to ABT-263 as a single agent daily for 2 weeks in achieving 
tumor-free survival in 100% of mice (Fig. 2.6A). Combination of ABT-263 and SAR405838 at 
their maximum tolerated dose (50 mg/kg for both) achieves complete tumor regression in 100% 
of the mice for 44 days in the RS4;11 xenograft model (Fig. 2.6B and C), much longer than both 
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drugs as single agents at 100 mg/kg. Both single agent treatments at 50 mg/kg fail to achieve 
tumor regression in 100% of mice. 
 These sequential and combination strategies using ABT-263 and SAR405838 were 
further evaluated in the MV4;11 xenograft model. In this model, ABT-263 is effective in 
inhibition of tumor growth but fails to achieve tumor regression, whereas SAR405838 at 100 
mg/kg for 18 days achieves complete tumor regression but tumors regrow shortly after the 
treatment ceases (Fig. 2.6). Consistent with the data obtained from the RS4;11 model, treatment 
with ABT-263 first daily for 9 days, followed by treatment with SAR405838 daily for 9 days, 
leads to longer tumor-free survival for mice than treatment with SAR405838 as a single-agent 
for 18 days (Fig. 2.6D). Similar to the data obtained in the RS4;11 model, the combination of 
ABT-263 and SAR405838 both at 100 mg/kg is toxic to mice bearing MV4;11 tumors. However, 
combination of ABT-263 at 50 mg/kg and SAR405838 at 100 mg/kg twice weekly for 3 weeks is 
well tolerated and yields prolonged tumor regression compared to SAR405838 at 100 mg/kg for 
18 days (Fig. 2.6E and F). 
 In summary, our study has shown that acute leukemia cells develop acquired resistance in 
vitro and in vivo when treated with either of two classes of apoptosis inducing agents, Bcl-2 
inhibitors or MDM2 inhibitors. The mechanisms of acquisition of resistance for these two 
different classes of drugs are however completely different. Understanding of the acquired 
resistant mechanisms led us to develop both sequential and combination treatment strategies with 
these two different classes of apoptosis-inducing agents, which can effectively improve the 
tumor-free survival of mice over the single-agent treatments, which should be explored in 
clinical trials for the treatment of acute leukemia.  
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Supplemental Information 
 
Figure S2.1 Characterization and sensitivity of ABT-737 resistant RS4;11 sublines isolated 
in vivo. 
A, Immunoblotting for Bcl-2 family members and GAPDH in RS4;11 parental, vehicle (30L and 
30R) and in vivo isolated sublines (G3M1-G3M8). B, Cells treated with ABT-737 for 4 days and 
cell viability was determined by WST assay. C, Cells were treated with ABT-737 for 24 h for 
apoptosis analysis by flow cytometry with Annexin V/P.I. double staining. 
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Figure S2.2 Variable Resistance to SAR405838 in the in vivo isolated RS4;11 sublines.  
A, Cells were treated with SAR for 24 h for apoptosis analysis by flow cytometry with Annexin 
V/P.I. double staining.  B and C, Immunoblotting showing the effect of SAR405838 after 24 h 
on apoptotic regulators as a function of dose. 
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Figure S2.3 Treatment with ABT-263 followed by second treatment with ABT-263 or 
SAR405838. 
A, Antitumor activity of RS4;11 xenografts treated with ABT-263 for 21 days at 100 mg/kg 
orally. B, Immunoblotting of BAX and BAK in sublines isolated from RS4;11 xenografts treated 
with ABT-263 first followed by a second treatment with either ABT-263 or SAR405838. C, 
Body weight change of mice in Fig. 2.3F. 
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Figure S2.4 Treatment with SAR405838 followed by second treatment with ABT-263 or 
SAR405838. 
A, Antitumor activity of RS4;11 xenografts treated with SAR405838 for 21 days at 100 mg/kg 
orally. B, Immunoblotting of BAX and BAK in sublines isolated from RS4;11 xenografts treated 
with SAR405838 first followed by a second treatment with either ABT-263 or SAR405838. C, 
Body weight change of mice in Fig. 2.4F. 
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Figure S2.5 Characterization of resistance and sensitivity of ABT-263 and SAR405838 in 
MV4;11 in vitro model.  
A, Cells were treated for 4 days with ABT-263 or SAR and cell viability was determined by 
WST assay. B, Resistant cells isolated from in vitro exposure to drug were treated with ABT-263 
or SAR for 48 h for apoptosis analysis by flow cytometry with Annexin V/P.I. double staining. 
C, Immunoblotting for p53, Bcl-2 family members and GAPDH in MV4;11 resistant cells 
isolated from in vitro exposure to drug. 
 
 62 
 
Figure S2.6 Suppression of BAX or BAK in MV4;11 cells.  
A, Immunoblots showing efficiency of lentiviral knockdown of BAX and BAK. B, Cells treated 
with ABT-263 for 4 days and cell viability was determined by WST assay. C, cells treated with 
SAR for 4 days and cell viability was determined by WST assay. D, cells treated with 500 nM 
ABT-263 or 5 µM SAR for 48 h for apoptosis analysis by flow cytometry with Annexin V/P.I. 
double staining. Asterisks indicate significant difference (P < 0.0001). 
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Figure S2.7 Suppression of p53 in MV4;11 confers resistance to SAR405838, but remains 
sensitive to ABT-263.  
A, Immunoblot showing efficiency of lentiviral knockdown of p53. B and C, Cells treated with 
SAR or ABT-263 for 4 days and cell viability was determined by WST assay. D, Cells treated 
with 500 nM ABT- 6   r   μM SAR for 48 h for apoptosis analysis by flow cytometry with 
Annexin V/P.I. double staining. Asterisks indicate significant difference (P < 0.0001). 
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Figure S2.8 Characterization of MDM2-p53 inhibitor resistant MV4;11 sublines isolated in 
vivo.  
A, MV4;11 xenograft tumors were treated with vehicle (grey), 100 mg/kg ABT-263 orally 
(dashed line) or 100 mg/kg of SAR orally (black, G3M1-G3M6) for 18 days. B, Tumor cells 
(G3M1-G3M6) isolated from MV4;11 xenografts were treated with SAR for 4 days and cell 
viability was evaluated by WST assay. C, Resistant cells isolated from in vitro exposure to drug 
were treated with ABT-263 or SAR for 48 h for apoptosis analysis by flow cytometry with 
Annexin V/P.I. double staining. D, Immunoblotting showing the effect of SAR after 24 h on 
apoptotic regulators as a function of dose. 
 
 
Figure S2.9 Activity of Bcl-2/Bcl-xL inhibitor in SAR405838 inhibitor resistant MV4;11 
sublines isolated in vivo.  
A, Tumor cells (G3M1-G3M6) isolated from MV4;11 xenografts were treated with SAR for 4 
days and cell viability was evaluated by WST assay. B, Resistant cells isolated from in vitro 
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exposure to drug were treated with ABT-263 for 48 h for apoptosis analysis by flow cytometry 
with Annexin V/P.I. double staining. 
 
Figure S2.10 Body weight change of mice. 
Body weight change in Fig. 2.6A (A), Fig. 2.6B (B) and Fig. 2.6E (C). Data shown are mean ± 
SEM for 6-8 mice. 
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Table S2.1 p53 sequencing results in RS4;11 sublines 
 
Table S2.2 Combination index values for inhibitory effects of ABT-263 and SAR405838 on 
cell growth at a 1:1 ratio on cell growth analyzed by WST assay after 4 days. 
 
Table S2.3 Combination index values for apoptotic effects of ABT-263 and SAR405838. 
Combination index values for apoptotic effects of ABT-263 and SAR405838 in the presence of 
increasing doses of ABT-263 and SAR405838 or combinations of the two agents at a 1:10 ratio 
for RS4;11 and a 1:1 ratio for MV4;11. Apoptosis was measured by Annexin V/P.I. double 
staining. 
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Chapter 3  
Critical difference in development of acquired resistance to MDM2 
inhibitor SAR405838 in vitro and in vivo 
 
Abstract 
 SAR405838 is a potent and specific MDM2 inhibitor currently being evaluated in Phase I 
clinical trials for the treatment of human cancer. In the present study, we investigated the 
development of acquired resistance to SAR405838 treatment in vitro and the lack of resistance in 
vivo using the SJSA-1 osteosarcoma cell line, which harbors amplified MDM2 gene and wild-
type p53. In vitro treatment of the SJSA-1 cells with SAR405838 resulted in acquired resistance 
to the drug. Analysis of these resistant cells showed that p53 is mutated in the DNA binding 
domain resulting in resistance to SAR405838 in vitro. Treatment of mice bearing the parental 
SJSA-1 xenograft tumors with SAR405838 led to rapid tumor regression, but tumors eventually 
returned after treatment cessation. A number of cell lines were established by culturing the 
regrown tumors and, surprisingly, these sublines showed minimal loss of sensitivity to 
SAR405838. Consistently, analysis of these sublines showed that p53 retains its wild-type status, 
with the exception of one subline, that harbored a single heterozygous mutation C176F located in 
the DNA binding domain. Computational modeling suggested that the p53 C176F mutant is still 
functional. Interestingly, cell lines established from xenografts of a representative subline 
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lacking the p53 C176F mutation treated with a second round of SAR405838 in vivo were still 
responsive to SAR405838, albeit with reduced sensitivity. Xenografts of a representative subline 
harboring the p53 C176F mutation treated with a second round of SAR405838 in vivo resulted in 
complete tumor regression. Our study showed that the SJSA-1 tumor cells acquired profound 
resistance to MDM2 inhibitor SAR405838 in vitro and developed inactivating p53 mutations in 
its DNA binding domain. Conversely, in vivo SJSA-1 tumor cells retained sensitivity to the 
MDM2 inhibitor after multiple treatment rounds of SAR405838. A deep sequencing study 
indicates that SAR405838 induces p53 mutations not initially present in the parental cell 
population. Our study suggests that tumor cells respond differently to drug treatment under in 
vitro and in vivo environments.  Furthermore, these data suggest that both in vitro and in vivo 
models of resistance should be investigated in order to better identify resistance that will occur in 
a clinical setting.   
 
Introduction 
 The tumor suppressor p53 is a regulator of cell cycle, apoptosis, DNA repair and 
senescence
1-4
.
 
Approximately 50% of cancers maintain p53 wild-type status, but its function is 
tightly controlled by its primary cellular inhibitor, the MDM2 oncoprotein
5-8
. MDM2 acts by 
blocking the transactivation domain of p53, resulting in inhibition of p53 function
9
.  p53 can 
activate MDM2 expression and upregulate MDM2 protein, which represses p53 by three 
mechanisms: 1) MDM2 binds to p53 and blocks its ability to activate transcription; 2) MDM2 
ubiquitinates p53 and promotes its degradation; and 3) MDM2 is involved in the nuclear export 
of p53, thus rendering p53 inaccessible to its target DNAs
6,10
. These three inhibitory mechanisms 
of p53 by MDM2 are mediated by their direct protein-protein interaction.  Due to the crucial role 
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of p53, targeting the MDM2-p53 interaction using non-peptide, cell permeable small-molecule 
inhibitors is being pursued as a new and novel therapeutic strategy for the treatment of human 
cancers retaining wild-type p53
9,11,12
. Recently, small-molecule inhibitors have been designed to 
block the MDM2-p53 interaction to activate p53.  Seven highly potent MDM2 inhibitors, 
including RG7112
13,14
 and SAR405838
15
, also known as MI-77301, designed in our laboratory, 
are now in clinical trials for cancer treatment.  
 One critical question in the development and use of MDM2 inhibitors for cancer 
treatment is their potential to select for or acquire p53 mutations. It is well known that p53 wild-
type cancer cells respond better to cancer therapies than p53 mutated cancer cells
16-18
. Current 
cancer treatments, such as radiation and chemotherapy agents that damage DNA can result in the 
acquisition of p53 mutations resulting in secondary cancers
19,20
.  Initially it was hypothesized 
that activation of p53 through a non-genotoxic method, for example the MDM2 inhibitors, would 
avoid selection or acquisition of p53 mutated cells. However, this hypothesis was disproven in 
studies utilizing Nutlin-3, a small molecule MDM2 antagonist
21-23
. These studies exposed 
osteosarcoma, neuroblastoma, rhabdomyosarcoma and melanoma cell lines to Nutlin-3 for 
extended periods of time in vitro, which resulted in highly resistant sublines
21,24
. Several varying 
p53 mutations were identified in the resistant sublines.  The authors state that because different 
p53 mutations were detected in separate experiments it can be argued that these mutated cells 
arose during the Nutlin treatment course and were not already present in the parental cell 
population.  Although these studies suggest that p53 mutated cells are not being selected for 
under drug pressure, no studies have analyzed the presence of p53 mutated cells in the bulk 
parental population of cells before exposure to drug.   
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 Despite impressive initial antitumor activity, the complete tumor regression in xenograft 
models of p53 wild-type cancers achieved by Nutlin and RG7112
25
 is transitory; tumors 
eventually regrew after the treatments were terminated, suggesting emergence of resistance. 
Such acquired resistance is in general, a major cause of cancer drug failure in clinical trials
26
. To 
date, MDM2 inhibitors mechanisms of acquired drug resistance have only been studied in 
sublines that have developed resistance after long term exposure to drug in vitro
21,24
, no studies 
have investigated acquired resistance developed in vivo to MDM2 inhibitors. Because a drug 
may induce different levels or mechanisms of resistance in vitro and in vivo environments
27-29
, 
we have investigated the development of resistance to MDM2 inhibitor SAR405838 both in vitro 
and in vivo in the MDM2 amplified osteosarcoma (SJSA-1) cell line. 
 Our study has elucidated critical differences in the development of resistance in vitro 
versus in vivo resulting in exposure to MDM2 inhibitors and has shed light on the critical 
question of whether resistance to MDM2 inhibitors results from acquisition or selection of p53 
mutated cells. Furthermore, we have identified that several rounds of SAR405838 treatment in 
vivo does not result in highly resistant cancer cells. 
 
Materials and Methods  
Reagents and antibodies. SAR405838 was synthesized using a method similar to that for MI-
888
30
.  The following primary antibodies were used: MDM2 (SMP-14, sc-965) and GAPDH (sc-
5778) from Santa Cruz Biotechnology, p53 (DO-1, OP43) from Millipore and p21 (12D1) from 
Cell Signaling. 
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Cell Culture, cell viability, and apoptosis assays. SJSA-1 cell lines were purchased from 
American Type Culture Collection (ATCC) and cultured as recommended.  Cell viability was 
evaluated by a WST-8 assay (Dojindo
31
).  Apoptosis was analyzed using Annexin V-FLUOS 
staining kit (Roche Applied Science, Indianapolis, IN).  
 
Stable short hairpin interfering RNA constructs. Published papers were used as guides to 
generate short 19-bp hairpins for RNA interference: p53 (nucleotides 611-629 Genbank 
NM000546)
32
. The oligonucleotides were annealed and ligated into a self-inactivating lentiviral 
vector under the control of the H1 promoter
33
.  The vector used was also designed to carry the 
GFP reporter gene under control of the human ubiquitin-C promoter to monitor infection 
efficiency.  A scrambled shRNA construct was also utilized as a control
32
.  Lentiviral shRNA 
virus-containing supernatant was generated by the University of Michigan Vector Core.  Virus-
containing supernatant was used to infect SJSA-1 cells.  At 96 h post-infection, the cells were 
sorted for GFP fluorescence and used for all subsequent experiments.  
 
p53 Mutation Analysis. The p53 status was determined by sequence analysis. Total RNA was 
extracted with RNeasy Mini Kit  from Qiagen Inc (Valencia, CA). Complimentary DNA 
(cDNA) was prepared by reverse transcription using SuperScript III First-Strand Synthesis 
SyperMix system from Invitrogen Corporation (Carlsbad, CA) following the manufacturer's 
protocol. Primers to amplify and sequence cDNA for exons 2 to 11 of human p53 were used 
from Aziz et al.
21
.  The amplified p53 cDNA was sequenced by the University of Michigan 
Sequencing Core. Mutation surveyor (SoftGenetics LLC) software was used to compare 
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experimental sequences against Refseq GenBank as well as by visual inspection of sequence 
tracings. 
 
In vivo xenograft studies. To develop xenograft tumors, 5 x 10
6 
tumor cells with 50% Matrigel 
were injected subcutaneously on the dorsal side of SCID mice. All groups had 6-8 mice. Tumor 
sizes and animal weights were measured 2-3 times per week with tumor volume (mm
3
) = (length 
x width
2
)/2. Tumor growth inhibition was calculated by the formula: 100%  x (mean volume of 
controls - mean volume of treated)/ mean volume of controls at end of treatment. 
 
Statistical Analysis. Differences in mean values of cell apoptosis among different groups were 
analyzed by 2-way ANOVA. For in vivo studies, significance (P) was calculated by Students t 
test, with a P value of less than 0.05 being considered significant.  All statistical tests were 2-
sided, and all statistical analysis was carried out using GraphPad Prism 6. 
 
PacBio Experiment.  
Amplification of TP53 was performed with PCR primers (see p53 Mutation Analysis). This 
amplicon was deeply sequenced on the Pacific Biosciences SMRT sequencer (PacBio).  From 
the one PacBio flowcell 61,438 reads were generated, 43,445 mapped to the TP53 mRNA 
consensus sequence. Reads were examined for minor variant detection, using the 
RS_Minor_Variant module from PacBio.   
 
Computational Modeling. The crystal structure of tetrameric p53 and the DNA of the BAX 
response element with the PDB entry: 4HEJ 
34
 was used in the computational modeling. In 
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preparation of the simulations, we have used the MOE program (Chemical Computing Group, 
Montreal, Quebec, Canada) to determine the protonation state of ionizable groups on p53 under 
the standard physiological condition. The MOE program was also used to perform the mutation 
of C176F in p53. In the C176F modeling, we selected the Phe rotamer that is not in van der Waal 
clashes with neighboring atoms. PMEMD from Amber (version 12)
35
 was used for molecular 
dynamics simulations. The Amber 99SB force field parameters
36
 were used for the amino acids. 
The force field parameters for the zinc ion were from Lu et. al
37
. 
 To prepare the topology and coordinate files, counter ions were added to neutralize the 
charges in p53/DNA first and the system is then placed in a 13Å octahedral box of water (the 
TIP3P
38
 water model). A minimization procedure of 1-1000 steps using conjugated gradient 
followed by 2000 steps steepest decent was first carried out. Then, a 500 ps constant volume and 
constant temperature (NVT) simulation was performed to raise the temperature of the system to 
298K while constraining backbone atoms with a 5 kcal/mol/Å
2
 force constant with reference to 
the crystal structure. A second 200 ps constant pressure and constant temperature (NPT) 
simulation at 298 K was performed while constraining backbone atoms with a 2 kcal/mol/Å
2
 
force constant with reference to the crystal structure. The system is then ready for the 6 ns 
production run in the isobaric isothermal (NPT, T = 298K and P = 1 atm) ensemble. A harmonic 
constraint with a 2 kcal/mol/Å
2
 force constant was applied to the backbone atoms of the DNA 
double helix to ensure its integrity during the simulations. The SHAKE
39
 algorithm was used to 
fix bonds involving hydrogen. The PME method
40
 was used and the non-bonded cutoff distance 
was set at 12Å. The time step was 2 fs, and neighboring pairs list was updated every 20 steps. All 
the graphics were prepared using the PyMol program.  
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Results 
Establishment and characterization of in vitro SJSA-1 sublines resistant to SAR405838 
 The MDM2 inhibitor SAR405838 effectively inhibits cell growth with IC50 = 120 nM in 
the SJSA-1 cell line, which has amplified MDM2 and wild-type p53 status (Fig. 3.1A). 
Figure 3.1 Characterization of MDM2-p53 interaction inhibitor resistant SJSA-1 sublines 
isolated in vitro 
A, SJSA-1 cells developed resistance to MDM2 inhibitor in vitro. Cells were treated for 4 days 
with SAR405838 and cell viability was determined by WST assay. B, Cells were treated with 
SAR405838 for 48 h for apoptosis analysis with Annexin V/P.I. double staining. Data (mean ± 
SD) are from triplicates, including both early (Annexin V-positive/PI-negative) and late 
(Annexin V-positive/PI-positive) apoptotic cells. C, Cells were treated with SAR405838 for 24 h 
for cell cycle analysis by flow cytometry with P.I. staining.  D, SCID mice bearing MIR2 tumors 
were treated with vehicle, 100 mg/kg or 200 mg/kg of SAR405838 by oral gavage for 14 days. 
 
 To investigate the acquired resistance of the SJSA-1 cell line in vitro to the MDM2 
inhibitor, the SJSA-1 cells were exposed to SAR405838 in vitro by two different protocols (SI 
Fig. S3.1).  We established an SJSA-1 subline (CMIR) by exposing SJSA-  c ll       μM  f 
SAR405838 for 72 hrs. The cells were then rinsed to remove SAR405838 and the remaining 
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cells were expanded in normal medium. This process was repeated 8 times and surviving cells 
were utilized for subsequent experiments (SI Fig. S3.1A). Conversely, an alternative protocol 
was used to establish SJSA-1 sublines (MIR1 and MIR2) by gradually increasing concentrations 
of SAR405838 (500 nM up to 20 µM) (SI Fig. S1B)
41
. These three SJSA-1 sublines exhibit 
>100-fold resistance to SAR405838 in a cell growth assay compared to the parental and control 
SJSA-1 cell lines (Fig. 3.1A). Resistance to SAR405838 was further confirmed by loss of 
apoptosis induction and cell cycle arrest (Fig. 3.1B and C).   
 Since the activity of MDM2 inhibitors is known to depend upon wild-type p53, we 
analyzed p53 mutation by sequencing exons 2-11 in the in vitro sublines obtained by 
SAR405838 treatment. All four SJSA-1 in vitro sublines and were found to harbor p53 
mutation(s) in the DNA binding domain (SI Table S3.1). 
 To further asses the resistance of the in vitro SJSA-1 sublines, we investigated the 
efficacy of SAR405838 in xenografts of MIR2, which harbors a R273C mutation in p53. MIR2 
xenografts treated with SAR405838 at both 100 mg/kg and 200 mg/kg daily for two weeks did 
not respond to treatment with no difference in tumor volume compared to the vehicle control 
group (Fig. 3.1D and SI Fig. S3.2A).  Tumors were harvested after treatment cessation and 
analyzed for p53 mutations. All harvested tumor cell lines harbored the initially present 
heterozygous R273C mutation (Table S3.1B). 
 Taken together, these data show that treatment of the SJSA-1 cell line in vitro by 
SAR405838 yielded SAR405838-resistant sublines with p53 mutation(s) that are resistant to 
both in vitro and in vivo exposure to SAR405838. 
 
Establishment and characterization of in vivo SJSA-1 sublines treated with one round of 
SAR405838 
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 In vivo treatment of the SJSA-1 xenograft tumors in mice with 100 mg/kg of SAR405838 
for two weeks induced rapid and complete tumor regression, which persisted for >40 days, but 
eventually the tumors returned (Fig. 3.2A and SI Fig. S3.2B). We isolated SJSA-1 tumor cells 
from the regrown tumors and established 5 sublines (7.2-7.4, 7.6 & 7.7).  While the SJSA-1 
parental cell line and the vehicle treated tumor subline (VH1) are highly sensitive in a cell 
growth assay to SAR405838, all the 5 sublines obtained from the SAR405838 treated tumors 
have IC50 values exhibiting a very subtle decrease in sensitivity with a 2 to 3-fold greater 
resistance than the control cell lines (Fig. 3.2B). Apoptosis and cell cycle analysis by flow 
cytometry confirmed that sublines remain sensitive to SAR405838, albeit with reduced 
sensitivity (Fig. 3.2C). We analyzed the p53 mutation status of the in vivo sublines obtained by 
SAR405838 treatment.  Analysis showed that four out of the five sublines retained p53 wild-type 
status, with the exception of one subline (7.2), that harbored a single heterozygous mutation 
C176F (Table S3.2). 
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Figure 3.2 Characterization of MDM2 inhibitor in vivo treated SJSA-1 sublines isolated 
after a single round of SAR405838 treatment 
A, SJSA-1 xenograft tumors were treated with vehicle or 100 mg/kg of SAR405838 orally for 14 
days. B, Tumor cells (7.2-7.4, 7.6 and 7.7) isolated from SJSA-1 xenografts and vehicle treated 
xenograft (VH1) were treated with SAR405838 for 4 days and cell viability was evaluated by a 
WST assay. C, Examination of apoptosis induction and cell cycle arrest by flow cytometry. Cells 
were treated with SAR405838 for 48 h for apoptosis analysis by flow cytometry with Annexin 
V/P.I. double staining. The ttest was used to compare in vivo sublines to parental SJSA-1 cells. *, 
P < 0.05. Cells were treated with SAR405838 for 24 h for cell cycle analysis by flow cytometry 
with P.I. staining.  D, Western blot analysis of p53, MDM2, p21 and GAPDH protein level in 
SJSA-1 parental, vehicle (VH1) and in vivo (7.2, 7.3 & 7.7) isolated sublines after 24 h treatment 
with SAR405838 at increasing  concentrations. 
 
 To investigate if the in vivo sublines obtained from treatment with SAR405838 still 
retained functional p53, we examined induction of p21 and MDM2 and accumulation of p53 
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protein by SAR405838 treatment. In all the sublines, including the subline which harbored a p53 
mutation, SAR405838 induces a dose-dependent increase of MDM2, p21 and p53 proteins, 
indicating p53 is still functional  (Fig. 3.2D). 
 These data show that SJSA-1 cells treated in vivo with SAR405838 do not develop 
resistance to SAR405838 after one round of treatment. 
 
Establishment and characterization of in vivo 7.6/SJSA-1 sublines treated with multiple 
rounds of SAR405838 
 In an attempt to isolate SJSA-1 cells resistant to SAR405838 after in vivo treatment, we 
treated the 7.6 subline (wild-type p53) xenografts with two more rounds of SAR405838 
treatment (Fig. 3.3A).  Mice harboring xenografts at approximately 100 mm
3
 were treated with 
100 mg/kg of SAR405838 for two weeks and tumors regressed during treatment. Tumors regrew 
after treatment cessation to approximately 100 mm
3 
and were treated with 200 mg/kg for 8 days 
and tumors regressed with no sign of toxicity (SI Fig. S3.2C).  Treated tumors were harvested 
and cultured resulting in 7 sublines (G2M1, G2M2, G2M4 - G2M8) along with two 
representative sublines established from the vehicle treated tumors (G1M2 and G1M6). 
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Figure 3.3 Establishment and characterization of in vivo 7.6/SJSA-1 sublines treated with 
multiple rounds of SAR405838 
A, 7.6/SJSA-1 xenograft tumors were treated with vehicle or 100 mg/kg of SAR405838 orally 
for 14 days followed by 200 mg/kg SAR405838 for 8 days. B, Tumor cells isolated from 
7.6/SJSA-1 xenografts and vehicle treated xenografts (G1M2 and G1M6) were treated with 
SAR405838 for 4 days and cell viability was evaluated by a WST assay. C, Cells were treated 
with SAR405838 for 48 h for apoptosis analysis by flow cytometry with Annexin V/P.I. double 
staining. The ttest was used to compare sublines (G2M1, G2M2, G2M4-G2M8) to 7.6 subline. *, 
P < 0.05.  Cells were treated with SAR405838 for 24 h for cell cycle analysis by flow cytometry 
with P.I. staining.  D, Western blot analysis of p53, MDM2, p21 and GAPDH protein level after 
24 h treatment with SAR405838 at increasing  concentrations. 
 
 Surprisingly, established cell lines treated in total with three rounds of SAR405838 only 
exhibited IC50 values with  >2 to 3-fold greater resistance than the control cell lines and no 
difference in sensitivity to the 7.6 subline and its vehicle controls (Fig. 3.3B). Analysis of 
apoptosis by flow cytometry confirmed that sublines (G2M5 - G2M8) were not significantly 
different in the level of induction by SAR405838 exposure compared to 7.6 subline and its 
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vehicle controls (Fig. 3.3C).  Furthermore, SAR405838 was still capable of inducing cell cycle 
arrest in all sublines treated in vivo with three rounds of SAR405838 (Fig. 3.3C). 
 We analyzed the p53 mutation status of these sublines obtained from xenografts of 
7.6/SJSA-1 (p53 wild-type status) treated with three rounds of SAR405838.  Analysis showed 
that all 7 sublines harbored a single heterozygous mutation C176F (Table S3.3). In order to 
determine if these sublines retained functional p53, we examined induction of p21 and MDM2 
and accumulation of p53 protein by SAR405838 treatment. In representative sublines 
SAR405838 induces a dose-dependent increase of MDM2, p21 and p53 proteins (Fig. 3.3D). 
 These data confirm that SJSA-1 cells that have undergone multiple rounds of 
SAR405838 treatment remain sensitive to treatment despite the development of a single 
heterozygous mutation C176F. 
 
Establishment and characterization of in vivo 7.2/SJSA-1 sublines treated with SAR405838 
 Next, we attempted again to isolate SJSA-1 cells resistant to SAR405838 by treating the 
7.2 subline (C176F) xenografts with another round of 100 mg/kg or an increased dose at 200 
mg/kg of SAR405838 (Fig. 3.4A).  Treatment with both doses of SAR405838 resulted in tumor 
regression with no observed toxicity (SI Fig. S3.2D), where the higher dose resulted in 5 out of 8 
mice with undetectable tumors by treatment end. Harvesting and culturing of the 200 mg/kg 
SAR405838 group resulted in the establishment of 5 sublines (G3M2, G3M3, G3M5 - G3M7).  
Similar to the 7.6 subline xenograft sublines, the 7.2 sublines exhibited IC50 values with  >4-fold 
greater resistance than the control cell lines and no difference in sensitivity to the 7.2 subline and 
its vehicle control (G1M4) (Fig. 3.4B). Analysis of apoptosis by flow cytometry confirmed that 
all sublines, other than G3M3, were not significantly different in the level of induction by 
SAR405838 exposure compared to 7.2 subline and its vehicle control (Fig. 3.4C).  SAR405838 
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was still capable of inducing cell cycle arrest in all sublines treated in vivo with three rounds of 
SAR405838 (Fig. 3.4C). 
 
Figure 3.4 Establishment and characterization of in vivo 7.2/SJSA-1 sublines treated with 
SAR405838  
A, 7.2/SJSA-1 xenograft tumors were treated with vehicle, 100 mg/kg or 200 mg/kg of 
SAR405838 orally for 14 day. B, Tumor cells isolated from 7.2/SJSA-1 xenografts and vehicle 
treated xenografts (G1M4) were treated with SAR405838 for 4 days and cell viability was 
evaluated by a WST assay. C, Cells were treated with SAR405838 for 48 h for apoptosis analysis 
by flow cytometry with Annexin V/P.I. double staining. The ttest was used to compare sublines 
(G3M2, G3M3, G3M5-G3M7) to 7.2 subline. *, P < 0.05. Cells were treated with SAR405838 
for 24 h for cell cycle analysis by flow cytometry with P.I. staining.  D, Western blot analysis of 
p53, MDM2, p21 and GAPDH protein level in SJSA-1 parental, 7.2/SJSA-1 subline (7.2), 
vehicle control treated 7.2/SJSA-1 sublines (G1M4) and 200 mg/kg SAR405838 treated sublines 
(G3M2, G3M5, G3M6, G3M7) after 24 h treatment with SAR405838 at increasing 
concentrations. 
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 We analyzed the p53 mutation status of these sublines obtained from xenografts of 
7.2/SJSA-1 (C176F) treated with 200 mg/kg of SAR405838.  Analysis showed that all 5 sublines 
maintained the single heterozygous mutation C176F (Table S3.4). In order to determine if these 
sublines retained functional p53, we examined induction of p21 and MDM2 and accumulation of 
p53 protein by SAR405838 treatment. In representative sublines SAR405838 induces a dose-
dependent increase of MDM2, p21 and p53 proteins (Fig. 3.4D). 
 These data confirm that SJSA-1 xenografts of 7.2 (C176F) remain sensitive to treatment 
with SAR405838. 
 
MDM2 inhibitor in vivo treated sublines are sensitive to SAR405838 compared to the 
highly resistant in vitro resistant sublines 
 In order to examine the difference in the level of resistance of the in vivo and in vitro 
exposed cells to SAR405838 we employed apoptosis, cell cycle and western blot assays.  In a 
cell growth inhibition assay SJSA-1 cells exposed to SAR405838 in vitro exhibit >100-fold 
greater resistance than the control cell lines versus the SJSA-1 cells exposed to SAR405838 in 
vivo which exhibit at most 6-fold greater resistance than the control lines (Fig. 3.5A).  Analysis 
of apoptosis by flow clearly shows that induction of apoptosis is completely abolished in the 
SJSA-1 cells exposed to SAR405838 in vitro harboring a R273C mutation in p53 compared to 
strong apoptosis induction in SJSA-1 cells exposed SAR405838 in vivo harboring either wild 
type or a C176F mutation in p53 (Fig. 3.5B).  SAR405838 exposure does not result in cell cycle 
arrest in sublines treated in vitro with SAR405838, whereas sublines treated with SAR405838 in 
vivo still induce cell cycle arrest in a dose dependent manner upon exposure to SAR405838 (Fig. 
3.5B).   
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 To further investigate the differences in acquired resistance of in vitro versus in vivo 
exposure to SAR405838 we analyzed the activation of the p53 pathway using western blot.  
Several representative SJSA-1 sublines treated in vivo with SAR405838 retained functional p53 
status, represented by induction of MDM2, p53 and p21 in a dose dependent manner upon 
exposure to SAR405838, albeit with slightly reduced potency (Fig. 3.2D, 3.3D, 3.4D and 3.5C). 
Conversely, no significant induction of MDM2 or p21 protein was observed in the sublines, 
which developed resistance in vitro to SAR405838 (Fig. 3.5C).  An induction of p53 protein was 
observed in both MIR1 and MIR2, however it is important to note that the untreated control had 
a higher p53 level compared to the parental line.  The increased protein level of p53 in the 
untreated MIR1 and MIR2 sublines is consistent with the likely increased stability of the mutant 
p53
3
. 
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Figure 3.5 MDM2 inhibitor in vivo treated sublines (7.2, 7.6, G3M6 and G2M6) are 
sensitive to SAR405838 compared to the highly resistant in vitro resistant subline (MIR2) 
A, SJSA-1 and representative sublines were treated with SAR405838 for 4 days and cell viability 
was evaluated by a WST assay. B, Cells were treated with SAR405838 for 48 h for apoptosis 
analysis by flow cytometry with Annexin V/P.I. double staining. Cells were treated with 
SAR405838 for 24 h for cell cycle analysis by flow cytometry with P.I. staining. C, Western blot 
analysis of p53, MDM2, p21 and GAPDH protein level in SJSA-1 parental, representative in 
vivo treated sublines and in vitro treated sublines (MIR1 and MIR2) after 24 h treatment with 
SAR405838 at increasing concentrations. 
 
 These data confirm that the level of resistance to SAR405838 in SJSA-1 cells exposed to 
SAR405838 in vitro versus in vivo is drastically different. 
 
Deep sequencing of p53 in the SJSA-1 parental cell population 
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 In order to determine whether a small population of p53 mutated cells were present in the 
SJSA-1 cell line we performed deep sequencing using the PacBio RS platform
42,43
.  Primers were 
used to amplify the DNA binding domain of TP53 and amplicons were deeply sequenced on the 
Pacific Biosciences SMRT sequencer (PacBio).  A distinct feature of this sequencing technique 
is that a single DNA amplicon can be sequenced multiple times by a DNA polymerase in a single 
run allowing for determination of a circular consensus (CCS)
42
.  We limited the analysis reads to 
those that contained a minimum of 5 subreads (passes around the circular amplicon molecule) 
resulting in a 0.01% error rate; although individual consensus sequences can still be near 1% 
error
44
.  This limitation resulted in 16,861 reads with an average of 11.3 passes and quality of 
insert equal to 0.993.  We examined these reads for minor variant detection and found that there 
were no mutations in the DNA binding domain of the TP53 gene. 
 Next, we examined the PacBio data by a different method in order to determine if there 
are single mutations that occur at any one position when analyzing reads that contained a 
minimum of 10 subreads.  This limitation resulted in an overall coverage of over 6,200 reads per 
position with a mean of 0.25% error across all positions with a standard deviation of 0.39%.  We 
identified 19 positions in the nucleotide sequence with a predicted variation at a single nucleotide 
position with over 1% (1.02 - 4.11%) (SI Fig. S3.3). Of these 19 positions none of the mutations 
matched with the mutations found by Sanger sequencing in the acquired resistant sublines. This 
leads us to hypothesize that the 19 positions determined to have mutations at the low percentage 
of 1.02 to 4.11% are most likely due to PacBio error.  However, overall these data suggest that if 
p53 mutant cells are present in the parental SJSA-1 cells and are selected for under drug 
pressure, it is at less than 1% of the population of cells.   
 
Computational modeling of the interaction between the C176F p53 mutation and DNA 
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 Our data clearly show that SAR405383 can effectively induce p53 activation in all SJSA-
1 sublines containing a single heterozygous C176F p53 mutation. In the crystal structures of 
wild-type p53 in complex with DNA
45,46
, C176, together with H179, C238, C242 residues, 
coordinates with a zinc ion and appears to be critical in maintaining the structural integrity of 
p53. Therefore, it was surprising that p53 with a heterozygous C176F mutation is functionally 
active as a transcriptional factor and we performed computational simulations to shed light on 
the structure and function for this heterozygous C176F p53 mutation. 
 p53 functions in a tetrameric unit in which two p53 monomers form a dimer to interact 
with DNA and two p53 dimers loosely interact to form a tetramer. The interaction interface 
between two p53 monomers are mediated via a hydrophobic interaction between 2-fold 
symmetrical positions of P177 and M243 from each monomer and the salt-bridge interaction 
between R181 of one p53 (denoted as p53A) and E180 of the second p53 (denoted p53B)
46
 as 
shown in Fig. 3.6. In a 6 ns molecular dynamics (MD) simulation of the wild-type p53 tetramer 
complexed with DNA, we found the interaction interface is well-maintained. The salt-bridge 
interaction between R181 (p53A) and E180 (p53B) and R181 (p53B) and E180 (p53A) 
maintained distances between CZ of R181 and CD of E180 at 4.20 ± 0.68, 4.8 ± 0.77, 4.07 ± 
0.20 and 4.17 ± 0.32 Å from MD simulation trajectories whereas they are 4.6, 4.8, 4.9, 5.0 Å in 
the crystal structure. 
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Figure 3.6 Modeling of the C176F mutation in p53 reveals the mutants' ability to bind 
DNA.  
A, The loop-sheet-helix interaction interface between two p53 revealed by the crystal structure 
(PDB entry: 4HJE). B, The same interaction interface between one p53 wild-type and one 
(C176F) mutants in the final snapshot from the 6 ns MD simulation. Green and blue colored 
protein correspond to one p53 in a dimer. The backbone of DNA are shown in the orange color. 
The zinc ion is colored in purple. Hydrogen bonds are depicted in red dash lines. C and D, Two 
types of interaction between the p53 wild-type and p53 (C176F mutant) found from the final 
snapshot of the MD simulation corresponding to FCCF p53 tetrameric arrangement. 
 
 Due to the fact that the C176F p53 mutation is heterozygous, each p53 tetramer consists 
of two p53 wild-type molecules and two C176F p53 mutants and consequently, there are a total 
of six possible structural models for a p53 tetramer. In four of these six models, a wild-type p53 
monomer molecule and a C176F p53 mutant monomer form a dimer which interacts with DNA. 
In two other models, two p53 wild-type monomers form a dimer and two C176F p53 mutant 
monomers form another dimer to interact with DNA. We denote these arrangements as FCCF, 
FCFC, CFCF, CFFC, FFCC, and CCFF, with C representing the wild-type p53 (C176) monomer 
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and F the C176F mutated p53 monomer (SI Table S3.5 and Fig. S3.4). We used the motional 
fluctuations of the p53 backbone atoms in these models and in the crystal structure to assess their 
structural stability. The FFCC model appears to be the least stable but the other five models have 
similar backbone motional fluctuations, when compared to the crystal structure. The FCCF 
tetramer appears to be the most stable. In each of the dimers, we also calculated the salt-bridge 
interaction distances between R181 and E180, an indicator of the structural stability of the dimer. 
The most stable FCCF tetramer also has a stronger R181 - E180 interaction than the other five 
models but this interaction is slightly weaker than in the wild-type p53 tetramer (SI Fig. S3.4). 
 Since the mutation of C176F results in a loss of zinc coordination, we analyzed the model 
structures of the FCCF tetramer from the MD simulations and compared them to those in the 
wild-type p53 tetramer to identify the additional stabilizing interactions. We found that C176F 
mutation allows the mutant to gain additional hydrophobic interactions with the M243 residue in 
a different p53 monomer and enhances cation-aromatic interactions with the zinc ion (Fig. 3.6C 
and D). These simulations therefore suggest that the p53 FCCF tetramer maintains its structural 
stability and its strong interactions with the DNA through those newly identified interactions and 
in this way, compensates partially for the loss of the zinc coordination with the C176 residue.    
 
Discussion 
 SAR405838 inhibits the interaction between p53 and its inhibitor MDM2 and activates 
p53 responses in cancer cells. To date, studies investigating the acquisition of p53 mutations in 
cancer cells after in vitro exposure to MDM2 inhibitors has fostered the idea that targeting p53 
will undoubtedly result in the development of deleterious p53 mutations
21,24
. In this study, we 
utilized the SJSA-1 cell line to establish in vitro and in vivo sublines that have been exposed to 
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the MDM2 inhibitor SAR405838. We identified that in vitro resistance sublines are highly 
resistant to SAR405838 due to p53 mutations that inhibit p53 activation whereas sublines 
established from xenografts treated with SAR405838 retain sensitivity to the inhibitor despite a 
uniformly identified single p53 mutation. 
 SAR405838 is highly effective in inducing apoptosis in the SJSA-1 cell lines in vitro, 
achieving complete regression of SJSA-1 xenograft tumors in mice, but only in vitro treatment 
leads to the development of sublines that have profound acquired resistance to the MDM2 
inhibitor.  The in vitro developed resistant cell lines were deemed highly resistant both in in vitro 
assays as well as in an in vivo study, where mice showed no response to the SAR405838 at either 
100 or 200 mg/kg oral daily dosing for two weeks (Fig. 3.1D).  Surprisingly, cell lines 
established from tumors treated with 100 mg/kg oral daily dosing for two weeks only resulted in 
a slight decrease in sensitivity to SAR405838 (Fig. 3.2).  Sensitivity to SAR405838 of these 
established cell lines (7.2-7.4, 7.6 and 7.7) was confirmed in vivo.  Our data show that in the 
7.2/SJSA-1 and 7.6/SJSA-1 xenograft models, treatment with SAR405838 at 100 mg/kg daily 
for two weeks results in partial tumor regression for most tumors with over 100% tumor growth 
inhibition compared to vehicle controls (Fig. 3.3A and 3.4A).  Furthermore, treatment of the 
7.2/SJSA-1 xenograft model at 200 mg/kg daily for two weeks results in rapid and complete 
tumor regression in over 60% of mice with the remaining tumors reaching partial tumor 
regression (Fig. 3.4A).  
 We next sought to elucidate whether the difference in the level of resistance to 
SAR405838 in in vitro versus in vivo exposure to drug is dependent on the mutation status of 
p53.  Whether a mutant is functional or not depends on the nature of the structural changes, 
which will affect the selectivity for various response elements such as p53 binding to DNA
47,48
.  
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Initially all p53 mutants were considered to have equivalent affects on the function of p53, 
however, it is now known that different mutants can alter p53 function in vastly different ways
49
. 
Currently, there are two categories in which p53 mutants fall: the first termed as 'contact 
mutations' affect amino acids that contact DNA thus preventing wild-type transcriptional activity 
and the second termed as 'structural mutants' that disrupt the three dimensional structure of the 
protein
46,47
. We have identified that the SJSA-1 cancer cells exposed to MDM2 inhibitor 
SAR405838 by two different in vitro exposure protocols uniformly results in the acquisition of 
p53 mutant resistant sublines (Fig. 3.1).  The SJSA-1 in vitro acquired SAR405838 resistant 
sublines harbor missense mutations located in the DNA binding domain of p53.  All of the p53 
mutations identified in this study have previously been identified in patient tumors (http://www-
p53.iarc.fr/). The "hot spot" R273C mutation identified in both MIR1 and MIR2 sublines and the 
C277F mutation identified in CMIR are both common contact mutations
46
. R273 plays a crucial 
role in docking p53 to the DNA backbone and C277 directly contacts DNA bases
48
. Mutations 
leading to a change in the amino acid at these positions can dramatically reduce the DNA 
binding affinity
49,50
. Our data supports that these mutants ability to bind to DNA is reduced or 
lost because the in vitro resistant sublines are unable to activate p53 target proteins, apoptosis or 
cell cycle arrest (Fig. 3.1 and Fig. 3.5).  
 In drastic contrast to the in vitro acquired resistant sublines, established sublines from 
SJSA-1 xenografts that underwent single or multiple rounds of in vivo exposure to SAR405838 
either maintain p53 wild-type status or acquire the C176F mutation in p53. Wild-type p53 amino 
acids C176, H179, C238 and C242 coordinate to a zinc ion to fold correctly
46
.  Our data shows, 
unlike previously investigated Zn-binding-site mutants such as "hot spot" mutants R175C and 
R175H, the heterozygous C176F mutation does not result in loss of function of p53.  
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Surprisingly, although C176F no longer coordinates to the zinc ion, the gain of hydrophobic 
interaction between C176F and M243 and neighboring hydrophobic side chain atoms 
compensates the loss. Taken together, the computational modeling of the heterozygous C176F 
mutant, in vitro and in vivo assays with the SJSA-1 sublines harboring the heterozygous C176F 
mutation lead us to conclude that p53 remains functional and responsive to SAR405838. 
 The emergence of p53 mutated cells under SAR405838 exposure raises the questions as 
to where these cells originate from. SAR405838 treatment may result in the expansion of p53 
mutated cell fractions already present in the parental SJSA-1 cell line.  In two previous reports, 
nutlin-3 treatment of parental cell populations resulted in the p53 mutated sublines
21,24
. Their 
data may not be sufficient to conclude that nutlin-3 induces p53 mutations versus selects for p53 
mutant cells already present in the parental population.  However, our deep sequencing data, in 
corroboration with our resistant studies, supports these previous studies by showing that no p53 
mutated cells are present at over 1% of the bulk population of SJSA-1 cells.  
 In conclusion, our results show that SAR405838 treatment of SJSA-1 xenografts does not 
result in resistance to the MDM2 inhibitor. Surprisingly, the SJSA-1 sublines established from 
several rounds of in vivo treatment with SAR405838 harbor a single heterozygous C176F 
mutation in p53.  Computational modeling of the C176F mutation shows that this mutated p53 
form is still able to bind DNA, which is also evident in in vitro assays showing that SAR405838 
is still able to activate p53 target proteins, apoptosis and cell cycle arrest. Conversely, 
SAR405838 exposure in vitro to SJSA-1 cells results in p53 mutated sublines that are highly 
resistant to SAR405838.  One critical difference is that in in vitro treatment, the drug is present 
at a constant concentration and poses a continuous high threat to the survival of tumor cells.  For 
in vivo treatment, the pressure from the drug for tumor cell survival fluctuates, as a result of the 
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pharmacokinetic effect. While development of p53 mutations has been shown here and in other 
studies to be a primary mechanism of resistance in vitro to MDM2 inhibitors
21,24
, our study 
shows that robust resistance does not develop in vivo to SAR405838 in the MDM2 amplified 
osteosarcoma (SJSA-1) cell line.  Evidence presented in this study leads to the conclusion that in 
vitro exposure to the MDM2 inhibitor SAR405838 does not reflect what will take place in a 
clinical setting. The in vivo development of sublines treated with SAR405838 may be a much 
more accurate example of what will occur in the clinic, which suggests that patients can undergo 
several rounds of SAR405838 treatment with little to no development of resistance. 
 
Supplemental Information 
 
Figure S3.1 SAR405838 exposure and treatment protocols for CMIR, MIR1 and MIR2 
resistant sublines 
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Figure S3.2 Body weight change of mice 
Body weight change in mice in Fig. 3.1D (A), Fig. 3.2A (B), Fig. 3.3A (C) and Fig. 3.4A (D) . 
Data shown are mean ± SEM for 6-8 mice. 
 
 
Figure S3.3 SJSA-1 parental cell population PacBio sequencing data. 
Data represented as a graph of the percent a mutation was detected at each individual nucleotide 
position of the DNA binding domain of p53. The nucleotide positions correspond to amino acids 
101 to 300. Vertical lines signify the location of the 19 positions with over 1% nucleotide 
variation. 
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Figure S3.4 The root-mean-square deviations of the p53 backbone atoms from the wild-
type crystal structures in four different tetrameric arrangements from the 6 ns MD 
simulations.  
The distances between R181 (Cz) and E180(Cd) in the pair of dimeric p53 proteins calculated 
from the MD simulations. The standard deviations were shown in error bars. The arrangement of 
monomer A, B, C and D were shown in the legend. 
 
 
 
Table S3.1 p53 sequencing results of SJSA-1 sublines established by in vitro exposure to 
SAR405838 
A, p53 sequencing of parental SJSA-1, vehicle treated SJSA-1 sublines and in vitro resistant 
SJSA-1 sublines. B, p53 sequencing of in vitro resistant MIR2 sublines established after in vivo 
treatment with vehicle (G1M3) or 200 mg/kg/day of SAR405838 for two weeks (G3M1, G3M3 
and G3M6). 
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Table S3.2 p53 sequencing results of SJSA-1 sublines established after in vivo treatment 
with 100 mg/kg/day of SAR405838 for two weeks 
 
Table S3.3 p53 sequencing results of 7.6/SJSA-1 sublines (no mutation) established after 
three rounds of in vivo SAR405838 treatment 
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Table S3.4 p53 sequencing results of 7.2/SJSA-1 subline (mutation C176F) established after 
in vivo treatment with 200 mg/kg/day of SAR405838 orally for two weeks 
 
Table S3.5 Root-mean square deviations of the wild-type and mutant p53 backbone atoms 
from the crystal structure and the distances between R181(Cz) and E180(Cd) in each 
dimeric p53 protein determined from the MD simulations. 
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Chapter 4  
Conclusion 
 The major findings of this dissertation are centralized around the goal of elucidation and 
development of more effective ways to treat cancer. I have investigated the mechanisms of 
resistance in cancer to both MDM2-p53 interaction inhibitors and Bcl-2/Bcl-xL inhibitors both in 
vitro and in vivo. I identified rational treatment strategies aimed at overcoming and 
circumventing resistance to these small molecule inhibitors.  Lastly, I addressed the differences 
that arise in the development of resistance to these inhibitors in vitro versus in vivo. 
 Acquired resistance of tumor cells to anticancer drugs is a major cause of cancer therapy 
failure in the clinic. Cancer associated mutations in p53 are often found in the p53 DNA binding 
domain resulting in the inability of p53 to bind DNA and activate transcription
1
.  In both acute 
leukemia models and in the osteosarcoma model (SJSA-1) of in vitro and in vivo acquired 
resistance to SAR405838, p53 mutations in the DNA binding domain were identified.  Our 
analyses showed that each of the acute leukemia resistant sublines either harbor an inactivating 
mutated p53 gene or contain p53 with compromised transcriptional activity. The SJSA-1 in vitro 
acquired SAR405838 resistant sublines harbor deleterious missense mutations located in the 
DNA binding domain of p53. As a result, these resistant sublines are not sensitive to SAR405838 
in vitro or in vivo. Overall, these data show that cancer cells that develop resistance to 
SAR405838 lack functional p53. 
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 We have investigated the acquired resistance mechanisms in vitro and in vivo to the Bcl-
2/Bcl-xL inhibitor ABT-737, as well as its orally active analogue ABT-263/navitoclax, which is 
currently in clinical trials for the treatment of several cancers including leukemia 
(http://clinicaltrial.gov). In both xenografts of relapsed acute lymphoblastic leukemia (ALL) 
model (RS4;11) and pediatric acute myeloid leukemia (AML) model (MV4;11), ABT-263 
induced rapid and complete tumor regression, but tumors regrew shortly after treatment 
cessation. In our ALL model of acquired resistance, we found decreased expression of BAX both 
in vitro and in vivo as a repercussion of exposure to Bcl-2/Bcl-xL inhibitors.  Both the RS4;11 
and MV4;11 models retain sensitivity to ABT-737/ABT-263 when BAK is down-regulated, but 
become highly resistant when BAX is down-regulated. These data emphasize the different roles 
of the pro-apoptotic BAX     BAX  r              r c ll’  r           Bcl-2/Bcl-xL inhibition. 
Furthermore, I have identified a new mechanism of acquired resistance to Bcl-2/Bcl-xL 
inhibitors, which differ from the previously identified mechanisms of resistance. 
 We have increased the depth of understanding resistant mechanisms to Bcl-2/Bcl-xL 
inhibitors and MDM2-p53 interaction inhibitors, paving the way to develop novel approaches to 
treating patients with reoccurring disease. Combination and sequential studies presented in this 
dissertation show that targeting both Bcl-2/Bcl-xL and MDM2 can achieve longer tumor free 
survival. Furthermore, I have investigated treatment strategies aimed at overcoming resistance to 
both Bcl-2/Bcl-xL and MDM2-p53 interactions inhibitors. 
 We define a targeted strategy to overcome ABT-263/navitoclax resistance in the 
intrinsically resistant MV4;11 model and in the RS4;11 model where resistance is driven by loss 
of Bcl-2 family member, BAX.  We employed MDM2-p53 interaction inhibitor, SAR405838, in 
vitro and in vivo to re-activate apoptosis and cell growth inhibition.  The apoptotic response of 
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p53 stimulation is typically mediated by its transcriptional upregulation of proapoptotic Bcl-2 
family members, such as PUMA and/or BAX
2-4
, thus the hypothesis is that the employment of 
SAR405838 will induce the reactivation of the Bcl-2 pathway leading to apoptosis
5
.  Our data 
fully supports this hypothesis shown both by activation of PUMA and key apoptotic markers in 
the RS4;11 sublines resistant to ABT-737/ABT-263. Importantly, in the RS4;11 model 
SAR405838 achieves rapid and complete tumor regression in xenografts resistant to the Bcl-
2/Bcl-xL inhibitor ABT-263. In the MV4;11 model initial treatment with ABT-263 does not 
result in tumor regression, however, immediate treatment with SAR405838 results in complete 
tumor regression. Taken together, these data show that MDM2-p53 interaction inhibitors can 
resensitize cancer cells resistant to Bcl-2/Bcl-xL inhibitors. 
 Excitingly, we have identified a strategy to activate apoptosis in highly resistant acute 
leukemia sublines independent of p53 status utilizing a Bcl-2/Bcl-xL inhibitor.  ABT-263 is 
effective in vitro at activating apoptosis and cell growth inhibition in MDM2 inhibitor resistant 
RS4;11 and MV4;11 sublines. Furthermore, when RS4;11 tumors initially treated with 
SAR405838 regrow, they become unresponsive to the second round of SAR405838 treatment 
but undergo rapid tumor regression when treated with ABT-263. This suggests that the strategy 
of treating dysfunctional or mutated p53 cancers with Bcl-2/Bcl-xL inhibitors should be explored 
in the clinic. 
 Combination using MDM2-p53 interaction inhibitors and Bcl-2/Bcl-xL inhibitors has the 
added advantage of inducing p53 target genes leading to apoptosis and cell cycle arrest along 
with inhibition of highly expressed antiapoptotic Bcl-2 family members, Bcl-2 and Bcl-xL.  
Further inhibition of antiapoptotic Bcl-2 proteins can be achieved by successful inhibition of 
MDM2 resulting in activation of p53 and an increase in PUMA, which has been shown to 
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antagonize Mcl-1
4
.  The ABT-263/SAR405383 combination in two acute leukemia xenograft 
models showed rapid and complete tumor regression with extended tumor free survival 
compared to single agent controls.  Noteworthy is the MV4;11 model was only treated twice 
weekly with ABT-263/SAR405838 combination.  Less frequent dosing of the drugs could both 
delay the onset of resistance and result in less toxicity in patients. Since Bcl-2 is overexpressed 
in acute leukemia and 80% of leukemia's retain p53 wild-type status, the targeted combination 
therapy proposed here would constitute a mechanism-based therapy with considerable clinical 
potential. 
 In order to elucidate the mechanisms of drug resistance, most studies have employed cell 
lines that have been exposed to drug in vitro and acquired resistance due to repeated and/or 
continuous exposure to drug
6-8
. Fewer investigations have utilized tumor cell lines, which 
developed resistance in vivo
9
. Based on findings presented in this dissertation, there are obvious 
differences in the mechanism of drug resistance and in the development of resistance when 
tumor cells are exposed to drug in vitro versus in vivo. One critical difference is that in in vitro 
treatment, the drug is present at a constant concentration and poses a continuous high threat to 
the survival of tumor cells.  For in vivo treatment, the pressure from the drug for tumor cell 
survival fluctuates, as a result of the pharmacokinetic effect
9
.  
 Differences were identified in the acute leukemia models when exposed to Bcl-2/Bcl-xL 
inhibitors in vitro versus in vivo.  ABT-737/ABT-263 is highly effective in inducing apoptosis in 
the RS4;11 model in vitro and achieving complete regression of RS4;11 xenograft tumors in 
mice, but both in vitro and in vivo treatments lead to the development of sublines that have 
profound acquired resistance to this class of drugs. The in vivo exposure of RS4;11 xenografts to 
ABT-737/ABT-263 resulted in loss of expression of BAX, but not BAK. In contrast, the in vitro 
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exposure of RS4;11 cells to the Bcl-2/Bcl-xL inhibitor resulted in the loss of BAX expression as 
well as increased expression of the Mcl-1 protein. The loss of BAX protein expression in the 
Bcl-2/Bcl-xL inhibitor resistant cell lines is a finding in contrast to most studies published thus 
far in the literature, where increased expression of Mcl-1 or Bfl-1/A1 confers resistance to Bcl-
2/Bcl-xL inhibitors
10-13
.  The in vitro exposure of the MV4;11 model to ABT-263 also resulted in 
increased protein expression of Mcl-1. Although MV4;11 tumor cells were sensitive to ABT-263 
in vitro, treatment in vivo illustrated MV4;11 cells are intrinsically resistant to the Bcl-2/Bcl-xL 
inhibitor, further emphasizing that sensitivity and resistance to drugs must be evaluated in vivo. 
 SAR405838 is highly effective in inducing apoptosis in the SJSA-1 cell lines in vitro and 
achieves complete regression of SJSA-1 xenograft tumors in mice, but only in vitro treatment 
leads to the development of sublines that have profound acquired resistance to the MDM2 
inhibitor. The SJSA-1 in vitro acquired SAR405838 resistant sublines harbor deleterious 
missense mutations located in the DNA binding domain of p53. Our data corroborates that these 
p53 mutants ability to bind DNA is reduced because the in vitro resistant sublines are unable to 
activate p53 target proteins, induce apoptosis or inhibit cell cycle. In drastic contrast to the in 
vitro acquired resistant sublines, established sublines from SJSA-1 xenografts that underwent 
single or multiple rounds of in vivo exposure to SAR405838 either maintain p53 wild-type status 
or acquire the heterozygous C176F mutation in p53. Our data show that the C176F mutation 
does not result in loss of function of p53.  Our modeling study suggests that although the C176F 
p53 mutant no longer coordinates to the zinc ion, the gain of hydrophobic interaction between 
C176F and M243 and neighboring hydrophobic side chain atoms partially compensates the 
loss
14
. Taken together, these data lead us to conclude that the p53 C176F mutated sublines retain 
functional p53 and are responsive to SAR405838 treatment. Our results show that SAR405838 
 106 
treatment of SJSA-1 xenografts does not result in resistance to the MDM2 inhibitor. Evidence 
presented in this study leads to the conclusion that in vitro exposure to the MDM2 inhibitor 
SAR405838 may not reflect what will take place in a clinical setting. Furthermore, these data 
suggest that both in vitro and in vivo models of resistance should be investigated in order to 
better identify resistance that will occur in a clinical setting.   
 In summary, I provided substantial evidence to support the hypothesis that resistance to 
small molecule Bcl-2/Bcl-xL and MDM2-p53 interaction inhibitors can arise and that 
understanding the mechanisms of resistance to these agents allows for the development of 
rational treatment strategies. Furthermore, I have elucidated differences in development of 
resistance in vitro versus in vivo to Bcl-2/Bcl-xL and MDM2-p53 interaction inhibitors. These 
studies contribute to the continuous effort to treat cancer effectively with small molecule 
apoptosis-inducing agents.  
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